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Allosteric integrase inhibitors reveal a role for integrase during HIV-1 maturation 
 
Abstract 
Integration of the DNA copy of the HIV-1 genome is an essential step for virus replication and is 
mediated by a homotetrameric complex of the viral protein integrase (IN) in association with the 
ends of linear viral DNA (vDNA). HIV-1 integrates into actively transcribed genes, a trait 
mediated by cellular host cofactor LEDGF/p75. LEDGF/p75 engages IN in a pocket formed by 
dimerization of the IN catalytic core domain, a region that has been validated as a drug target for 
allosteric IN inhibitors (ALLINIs). Previous in vitro work suggested that ALLINIs function 
through disruption of two integration-associated functions: IN-vDNA complex formation and the 
IN-LEDGF/p75 interaction. We now demonstrate that ALLINI potency is accounted for during 
the late phase of HIV-1 replication where the inhibitors block the formation of the viral core, 
converting the normally electron-dense conical core to an eccentric phenotype where the 
electron-density exists as a condensate situated between a translucent core and the viral 
membrane.  We have further elucidated the eccentric condensates to represent non-packaged 
viral ribonucleoprotein (vRNP) complexes and that either genetic or pharmacological inhibition 
of IN can impair vRNP encapsidation. Supplying IN in trans as part of a Vpr-IN fusion protein 
partially restored the formation of conical cores with the internal electron density. Moreover the 
ability of ALLINIs to induce eccentric condensate formation required both IN and viral RNA. 
Based on these observations, we propose an active role for IN during HIV-1 maturation that 
involves initiating core morphogenesis and vRNP encapsidation. 
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HIV-1 epidemic 
 In 2013, there were an estimated 1.6 million deaths from human immunodeficiency virus 
type-1 (HIV-1) infections (1). Historically known as human T-cell leukemia/ T-cell 
lymphotrophic virus III, HIV-1 was found to be the causative agent of acquired 
immunodeficiency syndrome (AIDS) in 1983 (2-4). At that time, an AIDS or HIV-1 diagnosis 
was a death sentence. Through targeting cells critical for proper immune function, HIV-1 
weakens the infected individual’s ability to combat normally encountered, opportunistic 
pathogens. In fact, increased incidence of the normally rare diseases of Kaposi sarcoma and 
pneumocystis pneumonia were the first indicators that instigated the hunt leading to the 
discovery of HIV-1 (5-7).  
 In a mere three decades, science has elucidated the most intimate details regarding the 
basic biology behind the HIV-1 viral lifecycle. This foundational work has led to the 
development and production of combination antiretroviral therapies that have transformed the 
future outlook for an infected individual. The first small molecule inhibitor of HIV-1 replication 
was FDA approved for clinical use within the United States in just four years post-identification 
(8). The combined government and science-fueled achievement introducing azidothymidine 
(AZT) into the clinic demonstrated that HIV-1 could be effectively inhibited within patients and 
therefore was a treatable disease (9). Although AZT monotherapy proved to be inadequate for 
long-term treatment (10, 11), the pace of discovery-to-clinic provided precedent for the 
development of other small molecule inhibitors against HIV-1. Multiple antiretroviral drugs 
targeting several key steps of viral replication soon followed suit (8). Distribution and effective 
modes of prescription within the United States led to the precipitous drop in deaths due to HIV 
infection in 1995 with a corresponding increase in people living with HIV (Figure 1-1) (12). This   
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Figure 1-1. CDC estimated number of AIDS deaths and diagnoses and estimated number 
of individuals living with HIV infection within the United States from 1981-2008 
 
Figure extracted from Center for Disease Control and Prevention, HIV Surveillance --- United 
States, 1981-2008, MMWR Morb Mortal Wkly Rep 60(21), (2011) 689-693. 
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was a monumental feat within science, government and medicine and continues to serve as the 
prime example of effective streamlining of drug development. Yet, despite all of our scientific 
and clinical progress, HIV-1 remains a global epidemic and the possibility of an effective cure 
and/or vaccine remains uncertain.  
 
The HIV-1 replication cycle: Virion assembly to proviral DNA 
 HIV-1 (species) belongs to the subgroup of Retroviridae (family) known as lentiviruses 
(genus) (13). Lentiviruses package their genomes into virions as single-stranded RNA and 
reverse transcribe this genetic information into DNA shortly after entry into a susceptible host 
cell. In order to remain a permanent feature of the host cell, the viral cDNA is integrated into the 
genome of the cell targeted for infection. The HIV-1 lifecycle occurs in a step-wise process and 
therefore can be divided into early and late stages (Figure 1-2). The integration step demarcates 
the transition from the early stage to the late stage of the retroviral lifecycle. Viral DNA 
integration accordingly switches a susceptible host cell that was the target of the infecting-virus 
(target cell) into a cell that is capable of producing new infectious viral progeny (producer cell).  
 Transcription of the integrated DNA and translation of the transcribed mRNA (which 
also serves as the viral genome) begin the late steps of HIV-1 replication. Subsequent to the 
formation of the RNA and protein components of the virus, the final steps of HIV-1 replication 
can be further divided into three main steps: colocation of viral components on the plasma 
membrane forming the immature virion (assembly), departure of the immature particle across the 
plasma membrane (budding), and cleavage of polyproteins to allow for their rearrangements into  
an infectious virion (maturation). The early stage of the viral lifecycle includes receptor-
mediated ingress into a target host cell (entry), conversion of viral genomic RNA into cDNA 
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Figure 1-2. HIV-1 lifecycle: Schematic of the early and late stages of virus replication 
The early stage of the HIV-1 lifecycle includes viral entry, reverse transcription (conversion of 
genomic RNA into DNA) and integration (insertion of the viral genomic DNA) into the infected-
host cell genome. The late stage begins by production of viral components through transcription 
and translation. Viral components assemble on the plasma membrane to form an immature virion. 
The non-infectious immature particle buds, and cleavage of the polyproteins allow for 
rearrangement/maturation into an infectious virion.  
Transcription 
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Maturation
Entry
Integration
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 (reverse transcription) and insertion of the viral genomic cDNA into the infected-host cell 
genome (integration).  
 
The viral components  
 The basic constituents of an immature HIV-1 particle are the viral envelope (Env) (120 
kDa), two copies of viral RNA (vRNA) (9.1 kb) and two precursor polyproteins, Gag (55 kDa) 
and Gag-Pol (160 kDa) (14-18). By utilizing polyproteins, HIV-1 minimizes the number of 
components that need to be directed to the site of assembly. The Gag precursor consists of 
structural proteins: matrix (MA), capsid (CA) and nucleocapsid (NC) as well as the C-terminal 
p6 protein that is critical for virus particle budding (see below). The Pol component of the Gag-
Pol is the precursor to the three viral enzymes: protease (PR), integrase (IN) and reverse 
transcriptase (RT). The Gag-Pol polyprotein is translated as a result of -1 ribosomal frameshift, 
wherein the overlapping ~250 nucleotides of the gag and pol genes are brought into the same 
translational frame resulting in a fusion Gag-Pol protein (19, 20). The frameshift occurs at a 
frequency of ~5% of Gag production allowing for coordinated production of structural-to-
enzymatic components (19).  
 
Late stage: Assembly, budding, and maturation 
 Only the Gag polyprotein is needed for the assembly and budding of immature particles 
to occur (21), indicating that all signals necessary for these steps can be accounted for within this 
protein (22). In fact, all structural components of Gag play crucial roles for assembly and 
budding. MA is the main mediator for targeting Gag to the plasma membrane, specifically to the 
inner leaflet of the lipid membrane (23). Plasma membrane targeting through MA is thought to 
regulated by interaction with tRNA (24), and achieved in a bipartite manner: 1.) a co-
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translational addition of a myristyl group to the N-terminal glycine of MA (in turn Gag and Gag-
Pol) increases the affinity for interaction with hydrophobic partners (25, 26); 2.) MA contains a 
cluster of basic amino acids that aid in MA binding to the acidic phospholipids of the plasma 
membrane (27). Once membrane associated, Gag continues to multimerize at the site of 
assembly through lateral addition, eventually forming an electron dense spherical structure 
protruding from the plasma membrane (28). The C-terminal domain of CA has a dimerization 
interface that serves to promote lateral association of Gag molecules during assembly (29). The 
basic residues of NC bind to RNA in a nonspecific manner and ultimately result in a scaffolding 
effect that corroborates the Gag oligomerization effort indirectly through RNA-mediated Gag-
Gag interactions (30, 31). This poises RNA as a structural element within the immature particle; 
the most testimonial evidence of this role has been elucidated through disruption of immature 
retroviral particles upon RNase treatment (32). The RNA scaffolding properties of NC are 
essential for assembly of immature particles in terms of wildtype (WT) NC (33), but can be 
functionally replaced by a polypeptide that is capable of forming strong interprotein contacts 
such as the MS2 bacteriophage coat protein, or the cyclic AMP response element binding protein 
(CREB) zipper (also known as leucine zipper) domain (34). This functional replacement of NC 
during assembly also negates the structural role of RNA (35), emphasizing the cooperation 
between the two elements in assisting Gag oligomerization.   
 HIV-1 genome packaging is quite efficient with nearly all particles containing a diploid 
genomic vRNA (17). Selective packaging of vRNA is accomplished through specific interaction 
between the zinc fingers of NC with the four stable stem-loops present at the 5’ end of unspliced 
vRNA; this area is collectively known as the psi (Ψ) region (36-38). vRNA dimerizes and 
becomes associated with a lower-order Gag multimer within the cytoplasm prior to diffusion to 
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the site of assembly (39, 40). In the cytoplasm, vRNA undergoes dynamic diffusion, only 
becoming membrane-associated upon expression of Gag (41). The selective incorporation of 
vRNA is not essential for assembly and budding, since nonspecific cellular RNA can replace the 
RNA utilized for the Gag-Gag interactions. Deletion of the Ψ region allows for the formation of 
virus-like particles (VLPs)-- HIV-1 structural particles that lack genomic vRNA (42).  
 The rate of HIV-1 particle formation increases with the amount of available Gag, but on 
average the assembly of an immature particle occurs within 5-6 minutes (43). Budding of 
assembled immature particles from the plasma membrane is accomplished by appropriating the 
host’s cellular endosomal sorting complexes required for transport (ESCRT) pathway. The p6 
region of the Gag protein recruits ESCRT machinery to aid in fission from the plasma membrane 
through two late-budding or L-domain motifs: ‘PTAP’ (44-46) and ‘YPXL’ (47). Consistent 
with this function, delta-p6 Gag expression results in immature assembled particles that remain 
attached to the plasma membrane via a thin membranous stalk (48).  Through p6 recruitment of 
ESCRT factors, fission and endocytic recycling occurs, allowing the completed immature 
particle to be released from the host cell. 
 Budded, immature particles are structurally characterized by uncleaved radially ordered 
Gag polyprotein with the MA domain remaining membrane-associated and the C-terminal ends 
pointing inward (membrane-MA-CA-NC-p6) as schematically illustrated in Figure 1-3 (49, 50). 
Maturation of the immature particle occurs immediately following and/or concomitant with virus 
budding (51). PR liberates itself from Gag-Pol via auto-processing (52), an event mediated by 
transient dimeric encounters of polyprotein (53). Mature, dimeric PR then goes on to catalyze 
cleavages at 10 sites within the Gag and Gag-Pol polyproteins within a tightly regulated series of 
reactions. Regulation is achieved with sequential processing controlled by rate of PR cleavage   
	   9	  
 
 
 
Figure 1-3. Immature and mature HIV-1 particles 
 HIV-1 buds as an immature, noninfectious particle. Uncleaved Gag polyproteins are radially 
ordered as diagramed to the right of a representative electron micrograph. The minority of Gag-
Pol protein is interspersed within the majority of Gag within the same orientation. PR self-
liberates and cleaves polyproteins in a tightly regulated manner, allowing for rearrangement of 
viral contents and formation of the mature, infectious virion. The protein sequence of the 
immature virion is maintained (membrane-MA-CA-NC-p6), with MA remaining in contact with 
the lipid membrane while CA encases the NC-condensed vRNA and viral proteins. 
  
RNA
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RTp51
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(54, 55). As most sites are dissimilar and variable, PR appears to recognize the overall shape of 
the cleavage site (56). The context in which the site exists in large part determines its rate of 
cleavage (57). The processed proteins radically rearrange to form the final infectious HIV-1 
virion. Maintaining the radial sequence of the immature particle (membrane-MA-CA-NC-p6), 
MA remains in contact with the lipid membrane within an unordered fashion (23). 
Approximately 1200 CA proteins arrange to form a conical encasement around the viral enzymes 
and NC-wrapped vRNA (or ribonucleoprotein (RNP)) (58). The RNP is typically found to reside 
within the broad region of the core (59), where CA core assembly may nucleate (60).  
 
Early stage: Entry, Reverse Transcription and Integration  
 To initiate membrane fusion, HIV-1 virions must first attach to the target host cell. 
Attachment can be aided through relatively nonspecific charge interactions (61) or by attachment 
factors (62-64). Interaction of the functional, virion-protruding Env glycoprotein spike with its 
primary receptor CD4 is an essential step for HIV-1 entry (65-68). Three molecules of non-
covalently linked surface gp120 and transmembrane gp41 compose one Env spike (69). 
Mathematical modeling indicates that each HIV-1 particle may contain as few as 2-3 Env spikes 
that are both functional and capable of interacting with a host target cell (70). Interaction of the 
native Env trimer with the primary CD4 receptor induces conformational changes within the 
spike that activate it (71, 72), allowing interaction with host cell co-receptor CCR5 (73-77) or 
CXCR4 (78). Co-receptor binding then induces exposure of the hydrophobic transmembrane 
gp41, allowing fusion of the viral membrane with the plasma membrane of the target cell (79, 
80).  
 Fusion results in the release of viral contents into the host cell cytoplasm, including the 
conical CA core that encases the RNP and viral enzymes. Since mutations that alter the stability 
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of the core (increase or decrease) attenuate reverse transcription, it is understood that the core 
must partially disassociate in order to allow viral DNA (vDNA) synthesis to ensue (81, 82). In 
fact, uncoating and reverse transcription appear to be intimately linked. Mathematical diagrams 
guided by soft matter physics indicate that the confinement forces caused by vDNA synthesis 
would result in core disassembly (83). There is some evidence in support of this model. 
Uncoating is modestly impaired when the vRNA template is modified so that vDNA synthesis 
will not form a three-stranded flap structure (‘central DNA flap’), suggesting that the post-
synthesis structure of the vDNA may play a role in initiating disassembly (84). Additionally, 
stalling of the reverse transcription complex (RTC) results in a delay in uncoating, further 
linking disassembly with vDNA production (85). It is reasonable that reverse transcription would 
be synchronized with uncoating in order to avoid diffusion of RT enzymes and/or the vDNA 
intermediates into the milieu of the host cell cytoplasm, yet still allow for active exchange of 
other essential constituents for vDNA synthesis (deoxyribonucleotide triphosphates).  
 RT is capable of utilizing RNA or DNA as a template. Beyond these synthesis 
capabilities, RT contains an RNase H domain that will degrade RNA only if it exists as an RNA-
DNA hybrid. RT utilizes both copies of its positive-sense genome to convert single-stranded 
vRNA into double-stranded DNA within the RTC (reverse transcription mechanism reviewed in 
(86)). HIV-1 primes vDNA synthesis with cellular tRNALys, 3 (87), which was selectively 
incorporated into the particle during virus production (88). Although the majority of reverse 
transcription occurs upon exposure to cytoplasmic deoxyribonucleotide triphosphates within the 
newly infected target cell, the addition of a few nucleotides to the HIV-1 primer can initiate 
vDNA synthesis within the matured viral particle (89). The metabolic state of the cell can affect 
the duration of synthesis (90), but full-length vDNA in typical activated or cycling cells can be 
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detected within 4 hours of infection, and continues to gradually increase until 8-12 hours post-
infection (91, 92).  
 The preintegration complex (PIC) is composed of full-length vDNA in complex with 
viral and cellular proteins carried from the RTC. The PIC contains all components necessary for 
successful import of the nucleoprotein complex into the nucleus and integration of vDNA into 
the host cell genome. In addition to the IN enzyme, examination of extracted PICs reveal that a 
number of viral proteins remain engaged: MA, Viral-protein R (Vpr), CA and RT (93-96). 
Within the PIC, four IN molecules bound to the two ends of newly synthesized full-length vDNA 
will complete two enzymatic reactions: 3’-processing and strand transfer (97-100). Unlike most 
retroviruses, where nuclear import can only occur during cellular division when the nuclear 
envelope is dissolved, HIV-1 can enter cells at any stage of the cell cycle (101, 102). Within non-
dividing cells, import through nuclear pores and association with host chromatin is mediated by 
interactions between CA and numerous cellular factors: nucleoporin (NUP) 358 (103, 104), 
NUP153 (104, 105), cyclophilin A (CypA) (106), transportin 3 (TNPO3) (107-109), and cleavage 
and polyadenylation specificity factor 6 (CPSF6) (110, 111). Subsequent to nuclear import, 
association with host chromatin is influenced by interactions between viral PIC proteins and 
cellular factors. Lens epithelium-derived growth factor (LEDGF)/p75, a chromatin-bound 
protein, interacts with IN (112-114), and is a major player in determining specificity of 
integration site selection (115-117). Other factors also influence the global selection of 
chromatin-- depletion or disruption of CA interacting proteins NUP358, NUP153 TNPO3 and/or 
CypA influence integration site distribution (103, 118-120). Moreover, a component of the 
nuclear pore basket that interacts with hypertranscribed regions of chromatin via nuclear 
extensions, tpr, has been recently identified to contribute to PIC positioning/integration site 
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selection (121). Upon association with host cell chromosomal DNA, IN catalyzes strand transfer 
(100, 122). Host cellular machinery repairs the resultant DNA breaks leading to a stably 
integrated HIV-1 provirus.  
 
Molecular mechanisms of HIV-1 integration  
 The IN protein, which contains 288 amino acids (32 kDa), is cleaved from the C-terminus 
of the Gag-Pol polyprotein during maturation. It is composed of three independent, functional 
domains: the N-terminal domain (NTD), catalytic core domain (CCD) and the C-terminal 
domain (CTD). The CCD of IN, which adopts an RNase H fold (123), contains the catalytic triad 
(D, D-35-E motif) that is indispensible for catalytic activity (124-126). The D, D-35-E amino 
acid active site is well conserved amongst retroviruses and retrotransposons (125). Initial crystal 
structures of the HIV-1 IN CCD domain found the two of aspartic acid residues of the catalytic 
triad (D64 and D116) were responsible for coordinating a single metal ion (127, 128), therefore 
it was originally unclear as to whether one or two metal ions were important for enzymatic 
function. Structure-based modeling grounded by the x-ray crystal structure of prototype foamy 
virus (PFV) IN in complex with its cognate vDNA substrate (129) has since resolved this 
discrepancy and has implicated the third active site residue E152 with D64 to be involved in 
metal cofactor coordination of the second metal cofactor (130). IN is a highly dynamic protein 
that in solution yields a variety of species including monomers, dimers, tetramers and higher-
ordered species (131). IN functions as a higher-order multimer (132, 133). Specifically, a pair of 
IN dimers bring together the vDNA ends to yield an IN tetramer (134). Processing of the 3’ ends 
of vDNA can occur as in the context of an IN dimer in vitro (135, 136), although seems likely to 
occur under physiological conditions in the context of the tetramer (137, 138). 
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Enzymatic activities: 3’ processing and strand transfer 
 IN catalyzes two in-line bimolecular nucleophilic substitution (SN2) reactions in a 
sequential manner: 3’ processing and strand transfer (100). After association with the long 
terminal repeats (LTRs) at the ends of vDNA, IN catalyzes a dinucleotide cleavage adjacent to a 
conserved CA sequence (97-99). Utilizing the metallic ion cofactor to activate the oxygen atom 
of a water molecule and to destabilize the scissile phosphodiester bond, a dinucleotide is 
eliminated from both ends of the vDNA (100, 139). This enzymatic cleavage creates a 3’ 
hydroxyl group (CAOH-3’) that will serve as the nucleophile in the subsequent strand transfer 
reaction. Utilizing chiral phosphorothioates and a pair of nucleases with strong stereospecificities 
to phosphorothioates, the strand transfer reaction was identified to occur through a one-step 
mechanism independent of a covalent intermediate (100), as was initially considered (140). For 
strand transfer, the metal ion cofactor serves to activate the 3’ hydroxyl group at the ends of 
vDNA and to destabilize the scissile phosphodiester bond of target DNA resulting in a staggered 
cleavage (Figure 1-4). HIV-1 characteristically cuts in a 5-base pair offset (141, 142). 
Concomitant with cleavage, the CAOH-3’ ends of the vDNA are joined to the 5’ phosphates of 
target DNA leaving a 5-base pair gap at each end. Host cell machinery repairs the DNA breaks 
and results in 5-base pairs of genomic sequence (target site duplication (TSD)) flanking the 
integrated proviral DNA. The length of the target site duplication correlates with the amount of 
flexibility necessary to fit the preferred local target DNA sequence into the active site of IN 
(143). The x-ray crystal structure of PFV IN in complex with a cognate vDNA substrate has 
provided significant insight into the molecular mechanism of retroviral integration (129).  PFV  
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Figure 1-4. HIV-1 Integration 
IN catalyzes a dinucleotide cleavage at the 3’ ends of newly synthesized viral DNA (3’-
processing) leaving an activated hydroxyl group at the end of an invariant CA. After association 
with target host cell DNA, IN catalyzes strand transfer. Concomitantly with cleavage, the CAOH-
3’ ends of the vDNA are joined to the 5’ phosphates of target DNA with HIV-1 IN leaving a 
characteristic 5-base pair gap at each end. Host cell machinery repairs the DNA breaks and 
results in TSD with 5-base pairs of genomic sequence flanking the integrated proviral DNA.   
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integration reaction intermediates consistent with the described mechanisms of 3’-processing and 
strand transfer have been elegantly determined in crystallo (137, 144).   
 
Class I and class II IN mutations 
 Altering the IN protein sequence of HIV-1 can result in a variety of phenotypic outcomes, 
beyond simply blocking the integration of vDNA (145-149). Replication blocks in reverse 
transcription, particle assembly and/or particle release have been documented to occur with 
various IN mutant viruses. Despite being unable to replicate within the context of the virus, IN 
recombinant protein with these same amino acid substitutions will often still support integration 
catalytic activity in vitro (150). Therefore, IN mutant viruses are categorized by their associated 
replication block: class I IN mutant viruses are solely defective for integration, whereas class II 
IN mutant viruses harbor replication blocks at other steps of the viral lifecycle (reviewed in 
(150)).  
 Changing any of the residues that constitute the catalytic triad D, D-35-E motif to alanine 
yields the class I IN mutant phenotype and these viruses are specifically blocked at the 
integration step; the E152K active site mutant virus, by contrast, exhibits class II defects (147, 
148). In addition to linear integrated provirus, retrovirus infection leads to two forms of 
circularized vDNA within the nucleus of an infected cell: 1-LTR circles and 2-LTR circles (151). 
The latter species may be representative of either autointegration or the ligation of the two 
vDNA ends (152). 1-LTR (147) and 2-LTR (146-148) circles are representative of dead-end 
products of reverse transcription and therefore will accumulate within the nucleus upon infection 
with a class I IN mutant virus. Pharmacological inhibition of integration through IN strand 
transfer inhibitors (INSTIs) likewise results in an increase in 1-LTR and 2-LTR circles (153).  
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 A block in reverse transcription is the most common pleiotropic defect associated with 
class II IN mutant viruses (145-149). Although interactions between RT and IN have been noted 
(154-156), the significance of this interaction in the context of an HIV-1 infection has yet to be 
established. Defective release of viruses that contain class II IN mutations is another reported 
phenotype, although this defect appears to be somewhat dependent upon the cell line utilized 
(157). For example, an IN deletion mutant (∆IN) virus displayed a 15-fold defect when made in 
HeLa cells, whereas when produced from human 293T or simian COS-7 cells only a 5-fold 
decrease in production was observed (158).  
 Another phenotype commonly coupled with class II IN mutant viruses is altered virion 
morphology (146). Specifically, the electron density that is normally situated within the conical 
core of a mature HIV-1 virion is present as an eccentric condensate adjacent to a translucent core 
and the viral membrane. Due to the lack of any other obvious candidates, the electron density 
within HIV-1 virions has long since been interpreted to represent the RNP. Empirical evidence to 
confirm this assumption has yet to be reported. Given this widely held assumption, the presence 
of the electron-density outside of the core suggests misplacement of the viral RNP. IN has been 
previously implicated in proper genome dimerization within the virions (159, 160), and has been 
shown to bind in vitro-selected RNAs with different affinities (161). In addition to class II IN 
mutant viruses, the eccentric virion core morphology has been seen under suboptimal doses of 
PR inhibitors (162, 163) and with improper Gag polyprotein processing (164). 
 Class II IN mutant viruses provided the first indication that IN may be involved in other 
steps of the replication lifecycle. The exact role(s) IN has beyond its catalytic activity remains 
incompletely defined.  
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Non-random integration site distribution: HIV-1 integration host factor LEDGF/p75 
 IN has been reported to interact with several host cell proteins, yet few have been 
established to have major influences on enzyme activity within the context of infection 
(reviewed in (165)). One such protein, LEDGF/p75, has been confirmed to play a critical role in 
determining integration site distribution. The preference of HIV-1 to integrate into the bodies of 
active genes has been well documented both in vitro (166-168) and within patients (169, 170). 
The conclusion that LEDGF/p75 played an essential role in determining integration site selection 
took several years to establish.  
 LEDGF/p75 is a chromatin-bound (171), transcriptional co-activator (172) that was first 
identified to interact with IN through coimmunoprecipitation (112, 113) and a yeast two-hybrid 
screen (114). Inclusion of purified LEDGF/p75 protein within in vitro HIV-1 integration assays 
stimulated IN activity (112, 173). Upon ectopic expression in animal cells, IN was found to 
accumulate within the nucleus (112, 174), and LEDGF/p75 knockdown through RNA 
interference (RNAi) caused IN to relocate to the cytoplasm (114, 175). Additionally, infection of 
cells depleted for LEDGF/p75 resulted in altered integration preferences among the genome 
(115). Taken together, these results suggested that LEDGF/p75 might serve to target IN to host 
chromatin. Despite this apparent chromatin-tethering role, the importance of LEDGF/p75 within 
the context of an infection remained a debated topic since infectivity was either not affected or 
only impaired 2 to 4-fold upon seemingly efficient RNAi knockdown (176-178). 
 Through use of a more intensified lentiviral vector-based RNAi system, Llano et al. (179) 
showed that the amount of residual LEDGF/p75 protein within the system correlated with the 
reductions observed in virus infectivity. Ultimately, complete removal of LEDGF/p75 from 
mouse (116, 117) and human (180, 181) cells through genetic knockout confirmed the critical 
	   19	  
role of the cofactor, since these cells were 5 to 12-fold less susceptible to HIV-1 infection than 
were matched control cells. These findings indicate that even a minute amount of LEDGF/p75 is 
able to support integration, speaking volumes for the high specificity of this cofactor interaction 
during integration. 
 The IN-LEDGF/p75 interaction is mediated by an evolutionarily conserved IN-binding 
domain (IBD) within the C-terminal region of the 530-residue LEDGF/p75 protein; specifically 
spanning amino acids 347-429 (173).  NMR revealed the IBD to form a compact right-handed 
bundle of five helices with the IN contact residues mapping to the interhelical loops on one side 
of the globular structure (182). Mutagenesis of the interhelical loops identified three hotspot 
contact residues (Ile-365, Asp-366 and Phe-406) that were crucial for interaction with IN (182). 
A subsequent X-ray co-crystal structure of the IN CCD dimer in complex with the IBD permitted 
a more in-depth illustration of the protein-protein interface of the interaction (Figure 1-5) (183). 
The hotspot residues of the IBD anchor ~1280 Å of protein surface into a hydrophobic pocket 
formed by the dimerization of two IN CCD chains (A and B) (183). LEDGF/p75 hotspot residue 
Asp-366 forms two hydrogen bonds with the backbone amides of IN residues Glu-170 and His-
171 in the A-chain of IN. Structure-based mutagenesis revealed that substitution of Asn for Asp 
at LEDGF/p75 residue 366 abolished the interaction of the mutant LEDGF/p75D366N with IN 
(182) and was furthermore incapable of back-complementing infection defects of LEDGF/p75 
depletions (116, 179). Single amino acid substitutions within IN reduced the apparent affinity of 
the protein-protein interaction, but did not largely impact the integration step within the context 
of infection (184, 185) as compared to a single substitution (D366N) within the LEDGF/p75 
protein, indicating that the amino acid side chains crucial for the interaction are chiefly donated 
by the host factor.  
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Figure 1-5. The IN-LEDGF/p75 interaction interface   
A cartoon representation of the integrase-binding domain (IBD) (raspberry) bound at the CCD-
CCD interface of two IN molecules (green/A-chain and purple/B-chain) from protein database 
code 2B4J. Hydrogen bonds between the Asp-366 residue of the IBD and the backbone amides 
of His-171 and Glu-170 are represented by dashed lines. The boxed area within the left is 
expanded to the right to illustrate the details of the IBD–CCD interaction. LEDGF/p75 contact 
residues Ile-365 and Asp-366 are labeled in italics; IN amino acid residues that participate in 
IBD binding pocket formation are also indicated. 
 
Figure adapted from Jurado & Engelman, Multmodal mechanism of allosteric integrase 
inhibitors, Expert Rev Mol Med. 15, (2013) e14. 
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Over-expression of an IBD-enhanced green fluorescent protein (eGFP) fusion protein 
resulted in a potent block to HIV-1 infection, demonstrating that the IBD was capable of 
trandominant inhibition through outcompeting endogenous LEDGF/p75 (179, 186). When HIV-
1 was serial passaged in these cells overexpressing an IBD fragment fusion construct, two 
resistance mutations within IN were selected: A128T in the B chain and E170G in the A chain 
(187). Both residues mapped to the IN-LEDGF/p75 interface, providing ex vivo data consistent 
with the IBD-CCD crystallographic structure. These findings importantly demonstrated that  
manipulating the LEDGF/p75-IN interaction could interfere with HIV-1 replication, thereby 
highlighting the interaction as a potential drug target. 
 
Suppression of HIV-1 replication  
 Due to the pre-existence or emergence of drug-resistant mutant viruses, combinations of 
antiretrovirals were identified to be a more advantageous form of treatment since monotherapy 
only resulted in success for limited durations within drug-naïve patients (188, 189). HIV-1 RT is 
inherently error-prone (190, 191). It is estimated that one mutation will be introduced for every 
103-104 nucleotides polymerized (192-194). The HIV-1 genome is ~104 nucleotides in length, 
thereby 1-10 mutations may be generated in each viral genome with every replication cycle. 
With an estimated production rate of ~1010 HIV-1 particles per day (195), there is enormous 
potential for generating genetic diversity that could result in reduced susceptibility to an 
antiretroviral compound. Mathematical modeling suggests that any anti-HIV-1 combination 
therapy would require at least three drugs in order to provide prolonged viral load suppression 
(189, 196-198).  
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Current therapeutic approach: Highly active antiretroviral therapy 
 Highly active antiretroviral therapy (HAART) is a combination of small molecule 
inhibitors that primarily target the essential enzymes of HIV-1 replication (199). HAART was 
widely introduced into the clinic after the inclusion of a PR inhibitor with two nucleoside 
analogues resulted in profound and sustained suppression of viral loads within HIV-1-infected 
patients (200, 201). Incorporation of the 2-target, 3-drug combination therapy into clinical 
practice directly resulted in declines in morbidity and mortality amongst HIV-1 infected 
individuals with advanced immune depletion (202). Success of the current therapeutic approach 
in large part is due to the decrease in probability of selecting for a virus clone with multiple drug-
resistant mutations and the fact that viral fitness is often compromised upon the acquisition of a 
drug-resistance mutation (203). 
 There are over thirty FDA-approved antiretroviral drugs amongst six different classes: 1.) 
nucleoside RT inhibitors, 2.) non-nucleoside RT inhibitor, 3.) PR inhibitors, 4.) IN inhibitors, 5.) 
fusion inhibitors, and 6.) entry inhibitors. As suggested by the names, the molecular target and 
mechanism of inhibition of each compound determines the class of the antiretroviral. The broad 
spectrum of classes provides a heavy hitting armory for treatment of HIV-1 infections. But 
beyond excellent drugs for prescription, effective therapy requires adherence, drug tolerability, 
and the lack of interactions with other medications. If any of these requirements are 
compromised, the evolution of drug resistance can more readily occur. For all antiretroviral 
classes, drug-resistant viruses have been documented in patients (203).  
 
Integrase strand transfer inhibitors 
 All clinically available IN inhibitors specifically target the strand transfer reaction of 
integration, and thereby are classified as INSTIs. Three INSTIs have been FDA approved and are 
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currently prescribed to patients: raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG). 
INSTIs bind within the active site of IN and act through displacing the terminal deoxyadenylate 
residue from the IN-vDNA complex (129). INSTIs contain both a metal-binding pharmacophore 
to sequester the active-site metal co-factors and a hydrophobic group to aid in interaction with 
vDNA and IN (129, 204). Specificity for inhibition of the strand transfer reaction is achieved 
through INSTIs preferentially interacting with the IN-vDNA complex (205), aided by extensive 
contacts with the vDNA ends (129).  
INSTI-resistant viruses most often arise through a primary alteration of the amino acids 
influencing coordination of the essential metal co-factors binding within the active site (N155 
and Q148) (129, 206). Replication capacity is reduced within these mutant viruses and therefore 
specific secondary mutations often accompany the primary mutations (reviewed in (203)). 
Regardless of the primary and secondary resistant mutations, cross-resistance amongst INSTIs is 
observed (207, 208). RAL and EVG select for similar resistance mutations (209). DTG, a 
second-generation INSTI, has a higher barrier to resistance than RAL and EVG (210). The 
distinct resistance profile of DTG has been proposed to be due to the significantly slower 
dissociation kinetics of DTG (71 hours) from the IN-vDNA complex as compared to RAL (8.8 
hours) and EVG (2.7 hours) (211). Several RAL and EVG-resistant mutations show low-level 
DTG-resistance, but DTG can still be effectively used to treat patients who have failed 
RAL/EVG therapies (212). DTG as a component of combination therapy has interestingly not 
yet led to DTG-resistance within treatment naïve patients (213).  Yet, since all three INSTIs bind 
within the same region of IN and have some level of cross-resistance, future development of IN 
inhibitors should focus on binding IN at alternative regions to avoid overlapping resistance 
profiles. 
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Targeting of IN-IN interfaces for successful allosteric inhibition of HIV-1 integrase activity 
There are several challenges when attempting to inhibit protein-protein interactions with 
small molecule inhibitors. Since the contact surface of a typical protein-protein interface 
(~1,500-3000 Å) far exceeds the interface formed between a protein and a small molecule (~300-
1000 Å), the essential interaction interface must be contiguous, with the presence of divots 
and/or pockets for the small molecules to occupy (214). A full characterization of the interaction 
interface is essential to assess the potential for drugability, since drug-targetable hotspot regions 
on essential interacting protein interfaces are rare finds. 
 
Small molecules that target the HIV-1 IN-IN interface 
In 2001, an x-ray crystallographic screen aimed at identifying antiretrovirals that bind the 
CCD of IN yielded small molecules that specifically bound at the interface of two IN CCD 
monomers (215). One of these compounds, 3,4-dihydroxyphenyltriphenylarsonium bromide, 
inhibited the 3’ processing and strand transfer activities of IN at micromolar concentrations in 
vitro (215). Derivatives of tetra-acetylated-chicoric acids, a group of molecules discovered in 
1999 to inhibit IN enzymatic catalysis in vitro (216), were additionally found to target IN at the 
dimer interface (217). Further characterization of the tetra-acetylated-chicoric acid derivatives 
showed that these small molecules in addition to inhibiting IN enzymatic activities in vitro also 
modulated the dynamic exchange between IN subunits within solution (131, 218). Another small 
molecule, 1-pyrrolidineacetamide, was discovered due to its ability to inhibit IN oligomerization 
on a vDNA substrate in vitro (219).  Molecular modeling supported by site-directed mutagenesis 
of recombinant protein suggested that 1-pyrrolidineacetamide bound within the IN-IN dimer 
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interface at a similar region as the tetra-acetylated-chicoric acid derivatives (219). These initial 
findings were the first indication that allosteric inhibition of IN activity was likely a viable route 
for antiretroviral development, since there were small molecules binding to IN within a region 
distinct from the active site that still inhibited IN catalysis (albeit, only one group demonstrated 
antiviral activity in these early studies). Additionally, these studies laid precedent for the 
LEDGF/p75 binding pocket potentially serving as a drugable target for small molecule 
disruption of an essential protein-protein interaction. 
 
Targeting the LEDGF/p75 binding pocket with small molecular inhibitors 
A coumarin-containing compound, originally identified within a screen for HIV-1 PR 
inhibitors, was found, in addition to inhibiting PR, to also block HIV-1 IN activity in vitro (220). 
Affinity-labeling, confirmed through site-directed mutagenesis of recombinant protein, mapped 
the binding site of the compound to IN amino acids residues 128-136 (221). In particular 
recombinant IN with Trp-132 mutated (W132A/W132G/W132R) resisted drug-action (221). 
Trp-132 is a key residue within the LEDGF/p75 binding pocket (Figure 1-5). The complete 
mechanism of action and the ability of the coumarin-containing compound to influence 
LEDGF/p75 binding was not assessed. Nevertheless this study indicated a novel drug-binding 
site within IN that appeared to overlap with the LEDGF/p75 binding pocket. 
A wide-variety of experimental approaches have resulted in the identification of an array 
of small molecules that inhibit the LEDGF/p75-IN interaction (222-227), but the most promising 
inhibitors to-date (228) spawned from the identification of a class of quinoline-based acetic acid 
derivatives (225, 226, 229).  Two separate groups utilizing vastly different small molecule 
screening techniques independently discovered a similar pharmacophore. A high-throughput 
	   26	  
screen for inhibition of IN 3’-processing activity yielded a series of tert-butoxy-(4-phenyl-
quinolin-3-yl)-acetic acids (tBPQAs; also known as non-catalytic site IN inhibitors (NCINI) (229, 
230). The second group utilized structure-based virtual screening to identify a hit compound 
LEDGIN-3 (225) that ultimately led to the synthesis of low-to-submicromolar inhibitors 
LEDGIN-6 and CX14442 (collectively known as LEDGF-IN inhibitors (LEDGINs)) (225, 231).  
Initial reports suggested different mechanism of action for these two independently 
discovered small molecules, despite the similar pharmacophores (Figure 1-6). The 
tBPQA/NCINIs were identified by their ability to inhibit 3’-processing activity (226), whereas 
LEDGINs were reported not to affect 3’-processing (inhibitory concentration at 50% (IC50) 
>250µM) (225). A study aimed at comparing the mechanism of action of the two representative 
inhibitors (LEDGIN-6 and BI-1001) found that both compounds displayed potent antiviral 
activity and inhibited the interaction between IN-LEDGF/p75 and 3’-processing and strand 
transfer activities in vitro (232). X-ray crystallography of these small molecules and other 
derivatives bound to the CCD-CCD interface of an IN dimer indicated that the quinoline-based 
acetic acid derivatives occupied the LEDGF/p75 binding pocket (225, 232-235). Since these 
small molecules bind IN at a region distinct from the active site, yet still inhibited IN catalysis, 
they are defined as bona fide allosteric IN inhibitors or ALLINIs. This report additionally 
implicated the quinoline-based acetic acid derivatives in obstructing proper dynamic exchange of 
IN subunits within solution. Specifically, through stabilization of an inactive high-order IN 
multimer, ALLINIs impeded the formation of IN on the vDNA. Initial in vitro work, thereby, 
indicated that ALLINIs appear to inhibit HIV-1 replicative capacity by a multimodal mechanism 
through exploitation of the multifunctionality of IN. ALLINIs represent a novel drug class that 
could inhibit HIV-1 replication at multiple steps (formation of enzymatically active IN on vDNA, 
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3’-processing, strand transfer, and LEDGF-IN binding) and thereby warranted a clearer 
elucidation of mechanism of action within the context of the virus lifecycle. 
In this thesis, I describe our investigations to uncover the antiviral mechanism of the 
recently discovered ALLINIs. In contrast to original considerations, we discovered that the small 
molecules, rather than primarily working during the early phase of replication, when IN is known 
to catalyze DNA integration, displayed full potency when drug exposure was limited to the late 
stage of HIV-1 replication. We defined that within an ex vivo system, ALLINIs primarily 
function through promoting higher-ordered IN multimerization to impede HIV-1 maturation. 
Exposure to the compounds during virus production results in the formation of an aberrant virion, 
where the electron density that is normally situated within a conical core is instead adjacent to a 
translucent core and the viral membrane. Tomo-bubblegram imaging revealed that the eccentric 
condensate adjacent to the translucent core was composed of the viral NC protein-- definitively 
implicating ALLINI treatment in the inability to successfully encapsidate the NC-encased vRNA 
into the core of the virus. We further discovered that the ability for ALLINIs to induce the 
aberrant morphology was dependent upon the presence of vRNA, suggesting a specific 
interaction between vRNA and IN. I propose that HIV-1 IN plays a direct role in proper capsid 
assembly and genome encapsidation.  
Lastly, we explored the impact of ALLINI exposure on integration site distribution. Our 
findings indicate that the continued development of ALLINIs, for use within the clinic, should 
target the IN multimerization functionality as opposed to inhibit LEDGF/p75-binding in order to 
ensure continuation of the non-oncogenic HIV-1 integration site distribution profile.    
	   28	  
Figure 1-6: Quinoline-based acetic acid derivatives  
 
Chemical structures of representative quinoline-based acetic acid derivatives: GS-B (230), 
LEDGIN-6 (231), BI-1001 (232), BI-D (236), BIB-2 (237). 
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Allosteric integrase inhibitor potency is determined through the  
inhibition of HIV-1 particle maturation 
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Abstract 
Integration is essential for HIV-1 replication, and the viral IN protein is an important 
therapeutic target. ALLINIs that engage the IN dimer interface at the binding site for the host 
protein LEDGF/p75 are an emerging class of small molecule antagonists. Consistent with the 
inhibition of a multivalent drug target, ALLINIs display steep antiviral dose–response curves ex 
vivo. ALLINIs multimerize IN protein and concordantly block its assembly with vDNA in vitro, 
indicating that the disruption of two integration-associated functions, IN catalysis and the IN-
LEDGF/p75 interaction, determines the multimode mechanism of ALLINI action. We now 
demonstrate that ALLINI potency is unexpectedly accounted for during the late phase of HIV-1 
replication. The compounds promote virion IN multimerization and, reminiscent of class II IN 
mutations, block the formation of the electron-dense viral core and inhibit reverse transcription 
and integration in subsequently infected target cells. Mature virions are recalcitrant to ALLINI 
treatment, and compound potency during virus production is independent of the level of 
LEDGF/p75 expression. We conclude that cooperative multimerization of IN by ALLINIs 
together with the inability of LEDGF/p75 to effectively engage the virus during its egress from 
cells underscores the multimodal mechanism of ALLINI action. Our results highlight the 
versatile nature of allosteric inhibitors to primarily inhibit viral replication at a step that is 
distinct from the catalytic requirement for the target enzyme. The vulnerability of IN to small 
molecules during the late phase of HIV-1 replication unveils a pharmacological Achilles’ heel 
for exploitation in clinical ALLINI development. 
  
	   32	  
Introduction 
HAART, which treats patients with combinations of antiviral drugs to suppress HIV-1 
replication, is the standard of care in the AIDS clinic (199). HAART is most often formulated 
from compounds that inhibit the activities of the viral RT and PR enzymes. The activity of the 
viral IN enzyme is also crucial to HIV-1 replication, and RAL, which was licensed by the US 
Food and Drug Administration in 2007, is the first-in-class INSTI (238). Although the INSTI 
EVG has since been licensed, IN mutations that confer resistance to RAL in large part convey 
EVG cross-resistance, thereby limiting clinical INSTI treatment options (239). DVG, an INSTI 
that remains active in the face of most RAL resistance mutations, may help to circumvent the 
limitation of cross-resistance to the current clinical IN inhibitors (239). INSTIs inhibit vDNA 
strand transfer activity by binding to the intasome nucleoprotein complex at the enzyme active 
site and displacing the terminal deoxyadenylate residue of retroviral DNA that would otherwise 
be used by IN to cut chromosomal DNA (129). Inhibitors that engage HIV-1 IN at sites separate 
from the active site, which should retain potency in the face of INSTI resistance mutations, are 
therefore an important class of investigational antiretroviral drug (240). 
HIV-1 preferentially integrates along the bodies of active genes (166), a trait that is 
largely attributable to an interaction between IN and the host protein LEDGF/ p75 (reviewed in 
refs. (241, 242)). LEDGF/p75 functions as a bimodal tether during integration: elements within 
its N-terminal region confer constitutive binding to chromatin, whereas a downstream IBD binds 
lentiviral IN proteins (173, 243). HIV-1 IN is composed of three domains, the N-terminal 
domain, the CCD, and the C-terminal domain, and LEDGF/p75 engages IN at a cleft formed 
through the dimerization of the CCD (183). IN is a highly dynamic protein that functions as a 
tetramer, and its assembly in the presence of viral DNA is critical to enzyme function (131, 244). 
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Small molecules that compete for LEDGF/p75 binding enhance IN multimerization in the 
absence of vDNA and accordingly allosterically inhibit IN activity (230-232). Although various 
terms, including LEDGINs for LEDGF/p75-IN inhibitors, have been coined for these 
investigational compounds, we prefer “allosteric IN inhibitor” or ALLINI to highlight the 
mechanistic basis of compound action (232, 236). 
Different classes of antiretroviral drugs display characteristic dose–response curve slopes 
in antiviral activity assays, which has important implications for the mechanism of drug action. 
IN is considered a monovalent INSTI target because these compounds display slope parameters 
of close to 1 (245). Because ALLINIs display significantly steeper slopes, IN by contrast 
behaves as a multivalent target for this drug class (232). The inhibition of two integration-related 
functions, IN catalysis and the IN-LEDGF/ p75 interaction, are proposed to underlie the 
multimodal mechanism of ALLINI action (230-232). Herein we show that ALLINI potency is 
accounted for during the late stage of HIV-1 replication. The ability for ALLINIs to engage and 
multimerize IN at a point in the viral life cycle when the virus is apparently unable to interact 
with the LEDGF/p75 host factor accounts for the unique pharmacology of this class of 
antiretroviral compounds. 
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Results 
 
ALLINI potency is accounted for during the late stage of HIV-1 replication.  
The ALLINI BI-1001 (Figure 1-6) displayed an effective concentration 50% (EC50) of 
5.8 µM in a spreading HIV-1 replication assay (232). IN catalysis is required during the early 
phase of retroviral replication (199) where the infection of SupT1 cells by an HIV-luciferase 
(HIV-Luc) reporter virus was potently inhibited by the INSTI RAL (Table 2-1). BI-1001 
concentrations of up to 50 µM, by contrast, failed to inhibit HIV-Luc. HIV-Luc producing 
HEK293T cells were therefore treated with BI-1001, which did not affect the extent of virus 
accumulation in the cell supernatant. Subsequent challenge of SupT1 cells revealed an EC50 of 
1.9 ± 0.2 µM despite omitting additional BI-1001 from the target cell cultures (Table 2-1). These 
results are consistent with a recent report that virus produced in the presence of LEDGIN 
Cx05045 is noninfectious (231), yet extend it to show that HIV-1 is significantly more 
vulnerable when it is exposed to an ALLINI in virus producer compared with challenge target 
cells. Because target cells treated with BI-D (Figure 1-6) are protected from infection by HIV-
Luc (236), we next used the more potent compound to dissect the full spectrum of ALLINI 
action. 
BI-D yielded an EC50 of 1.17 ± 0.1 µM with an accompanying slope of 1.3 ± 0.2 during 
the early or acute phase of infection (Figure 2-1, black line, and Table 2-1), indicating that IN in 
large part behaves as a monovalent target under these conditions (245). The potency of the 
inhibitor increased ∼13-fold, to 0.089 ± 0.023 µM, following titration on HEK293T producer 
cells. The slope of the dose–response curve, 2.4 ± 0.4, was moreover noticeably greater than 1 
(Figure 2-1 solid gray line). Because an EC50 of 0.090 ± 0.031 µM with an accompanying slope 
of 2.8 ± 0.4 was determined in the spreading replication assay (Figure 2-1 dashed gray line), we  
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Figure 2-1. BI-D potency is accounted for during the late phase of HIV-1 replication   
(A) Dose–response curves under the indicated conditions of drug treatment. Late phase and 
spreading replication EC50 values were not statistically significant (P = 0.94); error bars represent 
the variation obtained from two to three independent experiments. (B) Release of HIV- 1NL4-3 
from PBMC cultures following 24 h of BI-D (10 µM) or solvent control treatment at peak of 
virus replication. (C) Infectivity of ultrafiltered particles from B as assessed in CEMx174 5.25 
M7 indicator cells. Results in B and C are averages ± SDs from three independent experiments.  
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Table 2-1.    Antiviral EC50 values and slope parameters 
 
aAverage ± standard deviation of 2 independent experiments  
 bNA, Not applicable 
 cAverage ± standard deviation of 3 independent experiments 
 dND, Not determined 
 eData from ref. 232.  
 
 
 
 
 
 
 
  
  BI-1001 RAL BI-D 
Treatment condition EC50 (µM) Slope EC50 (µM) Slope EC50 (µM) Slope 
Target Cell  >50a NAb 0.003 ± 0.001c 1.2 ± 0.06c 1.17 ± 0.1c 1.3 ± 0.2c 
Producer Cell 1.9 ± 0.2c 2.2 ± 0.7c NDd NDd 0.089 ± 0.023c 2.4 ± 0.4c 
Replicative Spread 5.8 ± 0.1e 3.7 ± 0.2e 0.005 ± 0.002e 1.1 ± 0.1e 0.090 ± 0.031a 2.8 ± 0.4a 
	   37	  
 
conclude BI-D potency is principally accounted for during the late phase of HIV-1 replication. 
To address physiological relevance, peripheral blood mononuclear cell (PBMC) cultures were 
treated with 10 µM BI-D, a dose equivalent to ∼110 EC50 units, during the peak of HIV-1NL4-3 
replication. Similar levels of HIV-1 were produced from BI-D and DMSO-treated PBMCs (Fig. 
1B). Viruses were washed by ultrafiltration to remove excess drug before target cell infection. 
BI-D treatment rendered HIV-1NL4-3 noninfectious (Figure 2-1). 
 
ALLINIs inhibit the formation of the electron-dense HIV-1 core. 
Mutational studies provide precedent for the involvement of IN during the late stage of 
HIV-1 replication. IN mutant viruses are classified I or II based on the nature of associated 
replication block(s) (150). Class I mutants are specifically blocked for integration, whereas class 
II mutants are additionally defective for particle assembly/release and/or reverse transcription. 
The effects of ALLINI treatment were accordingly compared with two class II IN mutant viruses, 
V165A, which carries a missense mutation in the CCD (246), and ΔIN, which harbors a stop 
codon at the RT-IN boundary in the pol gene and hence does not express IN (146). Viral protein 
processing and virion incorporation were analyzed by metabolic labeling followed by 
immunoprecipitation. Consistent with prior observations (146), IN deletion altered the level of 
incorporated RT p66/p51 heterodimer (Figure 2-2A, lane 4). Neither BI-D treatment nor the 
V165A mutation reproducibly affected HIV-1 protein processing or virion incorporation (Figure 
2-2, lanes 1–3 and 6–8). The incorporation of HIV-1 genomic RNA into virions was also 
unaffected by BI-D treatment (Figure 2-2B). 
Virion morphology was analyzed by thin-section electron microscopy. Particles purified 
and concentrated by ion exchange and size exclusion chromatography (247) were categorized as  
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Figure 2-2. BI-D treatment does not affect HIV-1 protein processing or protein or genomic 
RNA incorporation into virions.  
(A) Fluorogram of immunoprecipitated 35S-labeled lysates of cell-free supernatants (lanes 1–5) 
or corresponding extracts of HEK293T cells (lanes 6–10) transfected with pNL43/XmaI 
encoding WT IN ± BI-D (lanes 6 and 7), V165A IN (lane 8), ΔIN deletion (lane 9), or no DNA 
control (lane 10). Migration positions of HIV-1 proteins and mass standards are indicated 
alongside the gel image. Quantification of IN-to-CA signals indicated no significant differences 
across lanes 1–3 (P = 0.23); results are representative of those obtained in four independent 
experiments. (B) RNAs isolated from HIV-1NL4-3 virions made from transfected HEK293T cells 
in the presence of DMSO or 10 µM BI-D were assessed for genome content by quantitative PCR. 
Averages of three independent experiments with associated SD are shown.  
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(i) mature, containing conical or round cores with associated electron density; (ii) eccentric, with 
electron dense material situated between translucent cores and the viral membrane; and (iii) 
immature. Most (93%) HIV-1NL4-3 particles were mature, whereas IN deletion yielded gross 
morphological defects (146): only ∼9% of particles were mature, with about 61% and 30% 
eccentric and immature, respectively (Figure 2-3). The V165A mutation yielded somewhat less 
intense alterations, with ∼18% of particles mature, 70% eccentric, and 12% immature. Similar to 
the class II mutations, ALLINI treatment significantly enhanced the formation of eccentric HIV-
1 cores. BI-D yielded ∼8%, 89%, and 3% mature, eccentric, and immature particles, respectively, 
whereas the values for BI-1001 were ∼17%, 76%, and 7% (Figure 2-3). 
 
ALLINI treatment renders HIV-1 defective for reverse transcription and integration.  
Quantitative PCR was used to assess the effects of ALLINI treatment on reverse 
transcription and integration. Primers and probes were designed to detect viral R and U5 (R-U5) 
sequences indicative of early reverse transcription (ERT) products, the late reverse transcription 
(LRT) product R-gag, integrated proviruses, and 2-LTR-containing circles that form at low 
levels in the nucleus through the action of cellular nonhomologous DNA end joining (248, 249). 
Integration specific blocks yield transient increases in 2-LTR circles due to the increased 
availability of nuclear viral DNA for cellular DNA metabolism (146, 153). 
HIV-Luc supported similar levels of LRT product formation in SupT1 cells treated with 
DMSO, RAL, or BI-D (Figure 2-4A). BI-D and RAL moreover both inhibited integration 
(Figure 2-4 B and C); the lack of 2-LTR circle increase in BI-D–treated cultures is likely 
attributable to relative drug dose (10 µM RAL = 3,333	  EC50 units, where 10 µM BI-D = 8.5 EC50 
units; Table 2-1). These results agree with prior reports that ALLINIs behave as  
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Figure 2-3. ALLINIs inhibit the formation of the electron-dense HIV-1 core. 
Upper, representative images of mature, eccentric, and immature particle morphologies. Lower, 
quantitation of core morphology frequencies (average ± SD for n = 2 experiments) for ΔIN, 
V165A, and wild-type HIV-1NL4-3 made in the presence of BI-D (10 µM), BI-1001 (50 µM), or 
DMSO solvent control. Particles (100 in each experiment) were counted and typed as described 
in text.  
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Figure 2-4. BI-D–treated HIV-1 is defective for reverse transcription and integration 
(A) DNAs isolated from SupT1 cells infected with HIV-Luc in the presence of DMSO (light 
gray squares), 10 µM BI-D (black circles), or 10 µM RAL (dark gray triangles) were assessed for 
LRT product formation by quantitative PCR. (B) Time course of 2-LTR circle formation. (C) 
Alu-PCR values at 48 h postinfection (DMSO sample set at 100%) for extracts described in A. 
(D) DNAs isolated from SupT1 cells infected with IN mutant V165A (dark gray triangles), or 
wild-type HIV-Luc pretreated during virus production with DMSO (light gray squares) or 10 µM 
BI-D (black circles), were assessed for ERT product formation. (E and F) Levels of LRT and 2-
LTR circle product formation, respectively, as a function of time. (G) Alu-PCR values at 48 h 
postinfection for extracts described in D; values obtained from DMSO-treated HIV-Luc were set 
at 100%. (H) Percentage of cells positive for betalactamase; similar results were found for HIV-
Luc carrying the HIV-1 Env glycoprotein. Results in A and C–G are averages and SDs of two 
independent infection experiments, with DNA samples queried in duplicate by PCR for each 
infection; B and H values are averages and SDs from three independent experiments.  
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integration inhibitors during the acute phase of HIV-1 replication (225, 230). Infection with 
virions produced in the presence of BI-D revealed strikingly different results. As expected (250), 
the V165A mutation reduced ERT and LRT product formation by ∼70%–80% (Figure 2-4D and 
E). BI-D–treated virus was also defective for reverse transcription, yielding 11%–18% of the 
level of ERT and LRT products compared with controls (Figure 2-4 D and E). The DNAs that 
did form were additionally defective for integration (Figure 2-4 F and G). Both BI-D–treated and 
V165A mutant virions entered SupT1 cells normally as assessed by the Vpr–beta-lactamase 
(Vpr-BlaM) fusion protein assay (Figure 2-4H). 
 
IN is the target of ALLINI action during viral egress.  
IN is processed from the Gag-Pol polyprotein precursor by the viral PR during HIV-1 
maturation (251). To investigate the nature of the drug target, ΔIN virions were 
transcomplemented with Vpr-IN harboring WT IN or the H171T IN mutant that carries a 
substitution in the ALLINI binding pocket (Figure 2-5A) and confers ∼44-fold resistance to BI-D 
(226). A similar experimental design previously demonstrated that Gag-Pol, and not IN, was the 
target of a dominant negative version of the IN-interacting INI1 host factor during HIV-1 egress 
(252). The ΔIN transcomplemented virions would accordingly resist BI-D action if the precursor 
Gag-Pol protein were the drug target. BI-D by contrast retained full potency, and the H171T 
mutation moreover conferred similar drug resistance profiles regardless of its expression in cis 
from Gag-Pol or in trans from Vpr-IN (Figure 2-6). We therefore conclude that IN is the likely 
target of BI-D action during the late stage of HIV-1 replication.  
Ultrafiltration was used to remove excess compound following incubation with cell-free 
HIV-Luc to assess virucidal activity. Despite testing concentrations of up to 100 µM, BI-D 
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Figure 2-5. BI-D–IN cocrystal structure and influence of BI-D on recombinant IN 
multimerization 
(A, Upper) Ribbon representation of the X-ray crystal structure of the HIV-1 IN CCD with two 
BI-D molecules (purple sticks) bound at the CCD–CCD interface (pdb code 4ID1). The CCD 
subunits are colored green and cream, with the carboxylate residues of the enzyme D,D-35-E 
active site residues in red sticks. (Lower) Rotated close-up view of BI-D within binding pocket. 
Residues that lie within 4 Å of the drug are highlighted in sticks, with hydrogen bond contacts 
between the BI-D carboxylate and backbone amides of IN residues Glu170 and His171 in red 
dashes. (B) Homogenous time resolve fluorescence (HTRF) readout of recombinant IN–IN 
binding as a function of BI-D concentration. Results are averages ± SD for three independent 
experiments. The HTRF signal in the absence of drug was 130 ± 16.5. 
 
A
B
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Figure 2-6. IN serves as the BI-D target during HIV-1 production 
HEK293T cells expressing HIV-Luc carrying WT or H171T IN, or HIV-LucΔIN 
transcomplemented with Vpr-INWT or Vpr-INH171T, were treated with the indicated 
concentrations of BI-D. Following transduction of SupT1 cells, the resulting levels of luciferase 
activity were normalized to control viruses constructed in the presence of DMSO. BI-D 
concentrations in the range of 0.05–1.0 µM, which inhibit WT IN containing viruses, stimulate 
H171T-expressing viral infectivities by ∼2.0–2.5-fold in biphasic fashion. Lower table, 
calculated EC50 values and slope parameters. Results are averages ± SD from three independent 
experiments.  
!
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IN  WT H171T Vpr-INWT Vpr-INH171T 
EC50 ( M) 0.083 ± 0.01
a >3  0.065 ± 0.03a  >3  
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antiviral activity was not detected. Consistent with its low micromolar virucidal activity (253), 
the nonnucleoside RT inhibitor (NNRTI) efavirenz (EFV) yielded an EC50 of 4.2 ± 3.5 µM (n = 
3). 
 
ALLINI potency is independent of LEDGF/p75 expression level during HIV-1 production.  
LEDGF/p75 and ALLINIs compete for binding to a pocket formed through the 
dimerization of the HIV-1 IN CCD (183, 225) (Figure 2-5A). To address if LEDGF/p75 affects 
BI-D potency, EC50 values were assessed in constitutively knocked down versus control 
HEK293T cells (176) (Figure 2-7). Consistent with results using mouse knockout cells (236), 
LEDGF/p75 knockdown yielded a significant 29-fold increase in BI-D potency during the acute 
phase of HIV-1 infection, whereas RAL potency was unaffected (Table 2-2). By contrast, 
LEDGF/p75 depletion did not significantly alter BI-D potency during HIV-1 production. 
Potency during the acute phase of HIV-1 infection in LEDGF/p75-depleted cells was moreover 
similar to BI-D titer during virus production regardless of LEDGF/p75 expression level (Table 2-
2). 
 
Purified protein and virion-associated IN are oligomerized by BI-D treatment. 
  Integration is catalyzed by an IN tetramer (134); in the absence of vDNA, recombinant 
HIV-1 IN assumes a variety of multimeric forms, from monomer to higher-order oligomers, 
depending on buffer conditions and protein concentration (254). Resonance transfer-based assays 
previously demonstrated that ALLINIs promote IN multimerization (230-232). HTRF (232) 
accordingly yielded an in vitro stimulatory concentration 50% of 0.027 ± 0.003 µM with an 
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Figure 2-7. Characterization of LEDGF/p75 knockdown cells 
Western blot of LEDGF/p75 (60.1 kDa) expression in nuclear and cytoplasmic extracts of 
constitutively knocked down 293T-si1340/1428 and 293T-siScram control cells. β-Actin (47 
kDa) was blotted as a loading control (Right). 
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Table 2-2. LEDGF/p75 expression level does not influence BI-D titer during the late phase 
of HIV-1 replication 
  RAL BI-D 
Treatment condition EC50 (µM) slope EC50 (µM) slope 
293T-si1340/1428 target cell  0.009 ± 0.001a 0.86 ± 0.13 0.131 ± 0.003b,d,e 0.85 ± 0.05 
293T-siScram target cell 0.01 ± 0.001a  0.94 ± 0.86 3.8 ± 1.1b 1.27 ± 0.67 
293T-si1340/1428 producer cell NDf NAg 0.161  ± 0.05c,d 2.40 ± 0.41 
293T-siScram producer cell NDf NAg 0.144  ± 0.07c,e 2.44 ± 0.12 
 aP = 0.79 
 bP = 0.016 
 cP = 0.56 
 dP = 0.46 
 eP = 0.84 
 fND, Not determined 
 gNA, Not applicable 	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accompanying slope of 1.97 ± 0.36 for BI-D (Figure 2-5B), and the compound expectedly 
cocrystallized in the LEDGF/p75 binding pocket at the CCD dimer interface (Figure 2-5A). Size 
exclusion chromatography was used to monitor distinct protein species, which revealed that BI-
D effectively converted IN tetramers to higher-order oligomers (Figure 2-8A). To assess effects 
of ALLINI treatment on IN multimerization during virus production, reducing agent was omitted 
from virion lysates (255), which revealed ∼3-fold enhancement of IN dimer formation by BI-D 
(Figure 2-8B, lanes 1–6). The substitution of Asp at position 124 in the ALLINI binding pocket 
(Figure 2-5A), which confers ∼250-fold resistance to BI-D (226), importantly negated 
compound-induced IN multimerization in vitro and in virions (Figure 2-8 A and B). 
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Figure 2-8. BI-D enhances the formation of IN oligomers 
(A) Elution profiles of purified wild-type (WT) and A124D mutant IN (20 µM) in the absence of 
drug (Upper) or in the presence of 10 µM BI-D. (B) Wild-type HIV-1NL4-3 and IN mutant T124D 
(position 124 is polymorphic; HIV-1HXB2 carries Ala where HIV-1NL4-3 harbors Thr) made in the 
presence of DMSO solvent control or 5 µM or 10 µM BI-D as indicated were prepared with and 
without DTT reducing agent in the SDS/PAGE sample buffer. Upper, blot was probed with anti-
IN monoclonal antibody 8E5; Lower, blot probed with anti-p24 antibody. Results are 
representative of three independent experiments. D, IN dimer; M, IN monomer; O, IN oligomer. 
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Discussion 
Some antiretroviral drugs, like potent NNRTIs, display weak activities (<1% of full 
potency) against secondary steps in the viral lifecycle (256). Low micromolar styrylquinoline-
based IN inhibitors can inhibit recombinant IN nuclear transport in vitro (257) and reverse 
transcription and integration during HIV-1 infection (258), although the contributions of these 
different activities to compound potency have remained unclear (259). The results reported here 
differ starkly from these prior reports: ALLINI potency is determined through the inhibition of 
viral core maturation, a step in the HIV-1 lifecycle that is clearly distinct from the catalytic 
requirement for the targeted IN enzyme (Figures 2-1 and 2-3 and Table 2-1). We expect that 
future allosteric inhibitors of viral targets will similarly unveil the versatile nature of these 
compounds to primarily inhibit replication in unanticipated ways. Because styrylquinolines 
harbor the quinoline pharmacophore common to many ALLINIs (Figure 1-6), it will be 
instructive to ascertain if they too impact late events in HIV-1 replication.  
Although there is strong consensus for a role for LEDGF/p75 during the early phase of 
HIV-1 replication, a potential postintegration role for this protein is less clear. Expression of a 
LEDGF/ p75-binding peptide in virus producer cells reduced HIV-1 infectivity (260). 
Overexpression of IBD-containing dominant interfering fragments by contrast potently restricted 
HIV-1 ingress, but not egress (186). Our finding that BI-D potency is unchanged by depleting 
LEDGF/p75 from virus producer cells is consistent with the fact that the IBD and ALLINIs 
engage the same CCD binding pocket on IN. We therefore conclude that ALLINI-mediated 
multimerization of IN through CCD dimer binding in the absence of competing LEDGF/p75 
protein during HIV-1 egress underlies the multimode mechanism of ALLINI action. Although 
our work indicates that inhibition of the interaction between IN and LEDGF/p75 or its close 
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relative hepatoma-derived growth factor related-protein (HRP)-2 does not significantly 
contribute to ALLINI potency (236) (Table 2-2), it nevertheless underscores the utility of 
searching for inhibitors of protein–protein interactions. ALLINIs can block the interaction 
between a physiologically relevant host factor and a viral protein dimerization interface, and we 
speculate that small molecules that block interactions between binding partners and target 
multimerization interfaces will allosterically alter target function even when the binding partner 
(e.g., recombinant antibody) plays a limited physiological role.  
INSTIs display slope parameters of ∼1 because each infectious particle yields a single 
intasome (129, 245). The underlying theme for steeper slopes, participation of multiple copies of 
the drug target in the relevant step of the lifecycle (245), is consistent with the results reported 
here for ALLINIs. The cooperative behavior of ALLINIs in IN multimerization assays (232) 
(Figure 2-5B), combined with the apparent inability of LEDGF/p75 to engage HIV-1 during 
virus egress, determines ALLINI potency (EC50 and slope parameter). Because LEDGF/p75 
depletion from target cells sharply increases BI-D EC50 values, the host factor competes with the 
drug for binding to the CCD dimer interface during the acute phase of infection (236). The slope 
of the dose–response curve remains close to 1 under this condition (Table 2-2) because only a 
minor fraction of the IN during viral ingress is required for intasome formation. IN therefore is a 
monovalent target of INSTIs and ALLINIs during the early phase of HIV-1 replication, where 
both types of compounds specifically target integration. We consider that inhibition of multiple 
viral replication steps (core formation, reverse transcription, and integration) could also 
contribute to the multimode mechanism of ALLINI action.  
Whereas INSTIs recapitulate the phenotype of class I IN mutant viruses, our findings 
highlight that ALLINI treatment during HIV-1 production induces the class II IN mutant viral 
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phenotype (Figure 2-3 and 2-4). The behavior of certain class II mutant viruses indicated a 
potential role for IN during the late stage of HIV-1 replication (150), although the underlying 
mechanism has remained elusive. The particle release defect of IN deletion mutant viruses is 
overridden by inhibiting PR activity (158), and suboptimal concentrations of PR inhibitors can 
yield the eccentric core morphology described here (162). One interpretation of our results is an 
active role for IN in the formation of the electron-dense HIV-1 core. However, structural 
rearrangements subsequent to Gag and Gag-Pol proteolysis that underlie HIV-1 core formation 
might by contrast be particularly sensitive to deregulated IN multimerization. Concordantly, a 
variety of mutations that either enhance or inhibit IN oligomerization confer the class II IN 
mutant phenotype (261-264). Although we cannot rule out that ALLINIs engage the IN domain 
of the Gag-Pol precursor protein before proteolysis, the results of Vpr-IN complementation 
assays indicate that the drug target during HIV-1 production is the postcleavage IN protein 
(Figure 2-6). ALLINIs lack virucidal activity because mature HIV-1 particles have proceeded 
past the point in the lifecycle where IN unveils a CCD–CCD Achilles’ heel for engagement by 
small molecule inhibitors. Further evaluation of class II mutant viruses may shed additional light 
on the multimode mechanism of ALLINI action. Hypersensitivity to multimerization inducing 
small molecules during viral egress highlights IN as an attractive target for clinical ALLINI 
development. 
 
 
  
	   53	  
Materials and Methods 
Plasmids and antivirals 
Plasmids pNL43/XmaI (265) and pNLX.Luc.R- (250) encode for HIV-1NL4-3 and single-
round HIV-Luc, respectively. FLAG-tagged HIV-1NL4-3-based bacterial IN expression vector 
was described previously (232); pCPH6PHIV1-IN (266) was used to express hexahistidine 
(His6) tagged HIV-1HXB2-based IN. Position 124 in IN, where notable ALLINI resistance can 
arise (226), is polymorphic (Thr in HIV-1NL4-3; Ala in HIV-1HXB2). Plasmid pMM310, which 
expresses the BlaM-Vpr fusion protein, was described (267), as were plasmids for expressing 
vesicular stomatitis virus G (VSV-G) and HIV-1 Env glycoproteins (250). Plasmid pNL43/XmaI 
encoding the V165A IN mutation was described (246); ΔIN deletion and T124D missense 
mutations were made by PCR-directed mutagenesis. The following plasmids were also altered by 
PCR mutagenesis to confer the associated IN changes: A124D in pCPH6P-HIV1-IN, and H171T 
in pRL2PVpr-IN (268) and pNLX.Luc.R-. Targeted mutations and absence of unwanted 
secondary changes were confirmed by dideoxy sequencing. 
BI-1001 and BI-D were synthesized as described (232, 236). RAL and EFV were 
obtained from the National Institutes of Health AIDS Research and Reference Reagent Program. 
 
Cells, viruses, and antiviral assays 
HEK293T cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented to contain 10% (vol/vol) fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 
µg/mL streptomycin. HEK293T cells that stably express LEDGF/p75-targeting shRNAs 
(293Tsi1340/1428) and a scrambled control sequence (293T-siScram) (176) were additionally 
maintained with 3 µg/mL puromycin–500 µg/mL hygromycin B and 500 µg/mL hygromycin B, 
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respectively. PBMCs isolated from human blood (Research Blood Components), SupT1 cells, 
and CEMx174 5.25 M7 indicator cells (269) were maintained in RPMI medium 1640 containing 
10% FBS, 100 IU/mL penicillin, and 100 µg/mL streptomycin. PBMCs were stimulated with 
phytohemagglutinin (5 µg/mL) for 48 h before infection.  
HIV-1NL4-3 infectivity (0.5 ng p24/mL) was determined using CEMx174 5.25 M7 
indicator cells. HIV-Luc was pseudotyped by cotransfecting HEK293T cells with pNLX.Luc.R- 
and an Env expression vector (HIV-1NL4-3 or VSV-G) using FuGENE 9 (Promega) (250). DMSO 
and ALLINIs were maintained in media throughout transfection procedures. Cell-free virus 
concentration, typically 500–800 ng/mL, was determined using a commercial p24 ELISA kit 
(Advanced Biosciences Laboratories). SupT1 (2 × 105/mL), CEMx174 5.25 M7 (2 × 105/mL), 
and shRNA-expressing HEK293T (1.5 × 105/mL) cells were infected in triplicate with 5 ng/mL 
p24, unless specified otherwise. Where indicated, compound or DMSO was added to target cells 
at the time of infection. Luciferase values, expressed as relative light units, were determined 48 h 
postinfection. Virucidal activity was analyzed after 1 h incubation with drug at 37 °C. Drug was 
removed before infection via three rounds of successive ultrafiltration in 100 kDa concentrators 
(Amicon), theoretically yielding a 28,000-fold reduction in the concentration of flow-through 
molecules. Stimulated PBMCs were infected with HIV-1NL4-3 (500 ng/mL p24) for 2 h. Residual 
virus was removed by washing cells three times. At the peak of replication (7 d postinfection), 
cells were washed before DMSO control or BI-D (10 µM) addition, and supernatant collected 24 
h later was ultrafiltered to remove excess drug. 
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DNA and RNA analysis 
DNA was extracted from SupT1 cells infected with ultrafiltered, DNase-treated (1 h at 
37 °C) HIV-Luc (100 ng p24/mL) using the DNeasy blood and tissue kit (Qiagen). Parallel 
infections were performed in the presence of 10 µM EFV to account for residual plasmid after 
DNase treatment, and values obtained from separate PCR assays were subtracted from 
experimental samples. Duplicate PCRs containing 25 ng DNA, 0.2 µM primers, 0.1 µM probe 
and 1× QuantiTect Probe PCR Master Mix were incubated at 50 °C for 2 min and 95 °C for 15 
min, followed by 40 cycles of 94 °C for 15 s, 58 °C for 30 s, and 72 °C for 30 s. Standards were 
prepared by diluting pNLX.Luc.R- (early and late reverse transcription) or pUC19.2LTR [2-LTR 
circles] (250) in DNA from uninfected cells. Primers AE2963/AE4422 and probe AE2965 were 
used to detect late reverse transcripts, whereas primers AE989/AE990 with probe AE995 were 
used for early reverse transcripts (116); 2–LTR circles were detected using primers 
AE4450/AE4451 with probe AE4452. Integration efficiency was measured by nested Alu-PCR; 
first round reactions used primers AE3014/AE1066, and second round real-time reactions 
contained primers AE3013/AE990 and probe AE995 (105). Integration standards were made by 
diluting DNAs from cells infected with wildtype virus under DMSO control	  conditions with 
DNA from uninfected cells. Values obtained from parallel reactions that omitted Alu-specific 
AE1066 primer from first round samples were subtracted from experimental Alu-PCR values.  
RNA was extracted from DNase-treated HIV-1NL4-3 (250 ng p24) made in the presence of 
DMSO solvent control or 10 µM BI-D using the viral RNA extraction kit (Qiagen). Triplicate 
PCRs containing 25 ng RNA, 0.2 µM of AE2963 and AE4422 primers, and 1× SYBR green 
Master Mix (Qiagen) with and without the supplied 1× RT mix were incubated at 50 °C for 30 
min and 95 °C for 15 min, followed by 40 cycles of 96 °C for 15 s, 55–90 °C for 30 s, and 72 °C 
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for 30 s. Genomic standards were made by diluting RNAs from the supernatant of cells 
transfected with pNL43/XmaI under DMSO control conditions. To account for signal from 
plasmid DNA that potentially remained from DNA transfection, values obtained in the absence 
of the RT mix were subtracted from the values obtained in the presence of the RT mix. 
 
Virion analyses 
HEK293T cells (9 × 105) were transfected with pNL4-3/XmaI-based plasmids (4.4 µg) 
using FuGENE 9. Cell-free HIV-1NL4-3 was purified from transfected HEK293T cell supernatants 
by ion exchange and size exclusion chromatography as described (247) before fixation and 
submission to the Harvard Medical School Electron Microscopy core facility. Images were taken 
with a JEOL 1200EX microscope equipped with an AMT 2k charge-coupled device camera. 
Images were visually scanned to count 100 viral particles per virus preparation. 
 
Vpr complementation assays 
HIV-1NLX.Luc.R-.ΔIN was transcomplemented with Vpr-IN by cotransfecting 
HEK293T cells with 1.8 µg pNLX.Luc.R-.ΔIN, 0.4 µg pRL2P-Vpr-IN containing the wild-type 
IN or H171T mutation, and 0.2 µg VSV-G expression vector. SupT1 cells (2 × 105/mL) were 
infected in triplicate with 5 ng/mL p24, and luciferase activities in cell extracts were determined 
at 48 h postinfection. HIV-1 entry was quantified by the Vpr-BlaM assay essentially as 
previously described (270). SupT1 cells infected for 4 h at 37 °C with 15 ng p24/mL HIV-Luc 
were washed and brought to room temperature before loading with the fluorogenic CCF2-AM 
substrate (Promega). Beta-lactamase activity was determined after 18 h via flow cytometry (BD 
Biosciences). 
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Radiolabeling and immunoprecipitation.  
Transfected HEK293T cells were metabolically labeled with [35S]Cys and [35S]Met (50 
µCi/mL each) at 24 h posttransfection for 16 h in Met−Cys− DMEM. BI-D was maintained at 10 
µM throughout transfection and labeling. Viral particles were pelleted from cell-free 
supernatants by ultracentrifugation at 4 °C for 1.5 h in a Beckman SW55 rotor at 27,000 rpm. 
Pelleted virions and cells were lysed in buffer containing 0.3 M NaCl, 50 mM Tris·HCl, pH 7.5, 
0.5% Triton X-100, 0.2 mM 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), and 100 
µg/mL leupeptin. Cell lysates were precleared with 50 µL protein A-Sepharose CL-4B beads 
(GE Healthcare) hydrated in PBS before immunoprecipitation. Viral and cell lysates were 
immunoprecipitated using antiserum from patients with AIDS (National Institutes of Health 
AIDS Research and Reference Reagent Program). Following extensive washing, proteins boiled 
from Sepharose beads were separated by SDS/ PAGE, and images of dried gels were developed 
using a Storm 820 PhosphorImager; signal intensities were determined using ImageQuant 
version 1.2 (GE Healthcare). 
 
Western blotting  
HEK293T cell supernatants from pNL43/XmaIbased transfections (9 × 105 cells) were 
pelleted by ultracentrifugation at 4 °C for 1.5 h in a Beckman SW55 rotor at 27,000 rpm. 
Pelleted virions were lysed in 20 µL SDS/PAGE sample buffer (0.3125 M Tris·HCl pH 6.8, 2% 
SDS, 10% (wt/vol) glycerol, 0.001% bromophenol blue) ± DTT. Lysed virions were fractionated 
by SDS/PAGE before immunoblotting IN with mouse monoclonal antibody 8E5 (271) at 1:5,000 
dilution. For LEDGF/p75 detection, cells were fractionated as described (272), and cytosolic and 
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nuclear extract protein concentrations were determined by Bradford assay (Pierce); 2 µg and 10 
µg of nuclear and cytoplasmic extract, respectively, was probed using a 1:10,000 dilution of anti 
LEDGF/p75 antibody A300-848 (Bethyl Laboratories). HRP-conjugated secondary antibodies 
(Dako) were used at 1:10,000. 
 
Homogeneous time resolved fluorescence and size exclusion chromatography 
Recombinant FLAG and His6-tagged HIV-1 IN proteins for HTRF assays were purified 
following expression in Escherichia coli as described previously (232). The IN–IN interaction 
HTRF assay was performed as described, with signals recorded on a Perkin-Elmer Multimode 
Enspire plate reader (232). WT and A124D INs for size exclusion chromatography (SEC) 
experiments were purified according to the method of Pandey et al. (273). SEC was performed 
over a Superdex 200 10/300 GL column (GE Healthcare) operated at 0.5 mL/min in buffer 
containing 20 mM Hepes, pH 6.8, 750 mM NaCl, 10 mM MgSO4, 0.2 mM	  EDTA, 5 mM β-
mercaptoethanol and 5% glycerol at 4 °C. IN (20 µM) was preincubated for 30 min with 10 
µMBI-D or DMSO solvent control before column injection. Protein elution was monitored by 
A280. 
 
X-Ray crystallization and structure determination 
The HIV-1 IN CCD (residues 50–212) containing the solubilizing F185K substitution 
was purified following expression in E. coli as described (123). The protein, concentrated to 8 
mg/mL, was crystallized at 4 °C using hanging drop diffusion against crystallization buffer 
containing 0.1 M Na cacodylate, pH 6.5, 0.1 M ammonium sulfate, 10% (wt/vol) polyethylene 
glycol 8000, and 5 mM DTT. Crystals reached 0.1–0.2 mm within 4 wk. Crystals were soaked in 
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5 mM BI-D dissolved in crystallization buffer containing 10% (vol/vol) DMSO for 8 h before 
flash freezing in liquid N2. Diffraction data were collected at 100 F on a Rigaku Raxis 4++ 
image plate detector at The Ohio State University Crystallography facility. Data intensity 
integration and reduction were performed using HKL2000 (274). The structure was solved by 
molecular replacement using Protein Data Bank (pdb) code 1ITG (123) with Phaser (275) in the 
CCP4 package (276). Coot (277) was used for subsequent refinement and to build the structure. 
Coordinates have been deposited in the Protein Data Bank under accession number 4ID1. 
 
Statistical analysis. Significant differences between data groups were determined by a paired-
sample t test (two-tailed). 
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Chapter 3 
 
Distribution and redistribution of HIV-1 nucleocapsid protein in immature, mature, and 
integrase-inhibited virions: a role for integrase in maturation 
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Abstract 
During virion maturation, HIV-1 capsid protein assembles into a conical core containing 
the vRNP complex, thought to be composed mainly of the vRNA and NC. After infection, the 
viral RNA is reverse-transcribed into double-stranded DNA, which is then incorporated into host 
chromosomes by IN catalysis. Certain IN mutations (class II) and antiviral drugs (ALLINIs) 
adversely affect maturation, resulting in virions that contain “eccentric condensates”, spherical 
electron-dense aggregates located outside electron-translucent cores. Here we demonstrate that in 
addition to the mislocalization of electron density, a class II IN mutation and ALLINIs each 
increase the fraction of virions with malformed cores (from ~12% to ~53%). Eccentric 
condensates have a high NC content as demonstrated by “tomo-bubblegram” imaging, a novel 
labeling technique that exploits NC’s susceptibility to radiation damage. Tomo-bubblegram 
imaging also localized NC inside wild-type cores and lining the spherical Gag shell in immature 
virions. We conclude that eccentric condensates represent non-packaged vRNPs and that either 
genetic or pharmacological inhibition of IN can impair vRNP encapsidation. Supplying IN in 
trans as part of a Vpr-IN fusion protein partially restored the formation of conical cores with 
internal electron density and the infectivity of a class II IN deletion mutant virus. Moreover the 
ability of ALLINIs to induce eccentric condensate formation required both IN and viral RNA. 
Based on these observations, we propose a role for IN in initiating core morphogenesis and 
vRNP encapsidation during HIV-1 maturation. 
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Introduction 
The formation of infectious HIV-1 particles starts with the co-assembly of the Gag and 
Gag-Pol polyproteins into a spherical shell, which buds from the cell to produce an immature 
virion (251). Following budding, the viral PR is activated and cleaves Gag and Gag-Pol into their 
component domains, of which the capsid protein CA assembles into a conical capsid shell 
containing the vRNA genome, NC, and replication enzymes (we use the term CA to denote the 
assembled protein shell and core for the CA plus whatever it may contain). This transformation 
is known as HIV-1 maturation. Drawing mainly on studies by cryo-electron tomography (cryo-
ET), a technique that allows 3D imaging of individual pleomorphic particles with good 
preservation of native structure (e.g. (278)), a number of different models explaining how CA 
can assemble into conical cores have been proposed (59, 60, 279, 280). However, maturation – 
which is the process targeted not only by protease inhibitors (PIs) (281) but also by ‘maturation 
inhibitors’ that act by denying PR access to a key cleavage site (282, 283) – is incompletely 
understood. 
 Mutational studies of the viral enzyme IN have demonstrated that the effects of some 
amino acid substitutions – the so-called class II IN mutations – include defects in particle 
assembly and reverse transcription (compared to class I IN mutations, which only affect 
integration) [reviewed in (150)]. Class II IN mutant viruses provided an initial clue for a role of 
IN in the late stages of replication, including maturation. More recently, a group of 
investigational compounds, 2-(quinolin-3-yl) acetic acid derivatives, which we refer to as 
ALLINIs (232) but are also called NCINIs for non-catalytic site IN inhibitor (284), LEDGINs 
for LEDGF-IN inhibitor (225), INLAIs for IN-LEDGF/p75 allosteric inhibitors (234), and 
MINIs for multimeric IN inhibitors (228), were found to inhibit HIV-1 infection (225, 229). 
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ALLINIs engage the interface that is formed by two molecules of the IN catalytic core domain at 
the binding pocket for the cellular integration co-factor LEDGF/p75 (225, 228, 230, 232-235), 
which itself guides vDNA integration to active genes [reviewed in (285)]. Inhibition of the 
LEDGF/p75-IN interaction was initially thought to underlie the mode of ALLINI action (225). 
However, the compounds were since discovered to affect the late stage of HIV-1 replication in a 
manner that is independent of LEDGF/p75 expression (180, 228, 233, 284, 286). The compounds 
are also active during the early stage of HIV-1 replication, but require much higher 
concentrations to achieve similar potencies as compared to when virus producer cells are treated 
(180, 228, 233-235, 284, 286). Akin to several class II IN mutant viruses, particles produced in 
the presence of ALLINIs are reportedly defective for multiple steps of HIV-1 replication, i.e.: 
maturation (228, 233, 284, 286), reverse transcription (228, 233, 284, 286), nuclear import of the 
vDNA (286), and integration (225, 228, 230, 233, 234, 284, 286). The ability of ALLINIs to 
induce higher-order IN oligomerization during virus production underlies their antiviral activity 
(228, 230-235, 237, 284, 286). 
Transmission electron microscopy of thin sections of plastic embeddings (referred to 
hereafter as TEM) of HIV-1 particles generated in the presence of ALLINIs revealed an apparent 
uncoupling of the incorporation of the vRNP complex - assumed to be composed primarily of 
vRNA and NC – from assembly of the capsid (228, 233, 284, 286). Instead of a normal electron-
dense core, a relatively electron-translucent core was observed, accompanied by a roughly 
spherical electron-dense feature, situated between the viral envelope and the translucent core. We 
refer to this feature as an “eccentric condensate”. It follows that ALLINIs can be useful probes to 
help understand how IN contributes to maturation, in a similar way that maturation inhibitors 
(which prevent the scission of the CA-SP1 junction within Gag, the final proteolytic cleavage 
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that leads to the generation of a mature core (287, 288), or mutations that prevent the cleavage of 
the Pol polyprotein (289, 290), have provided structural insights.  
In this study, we first analyzed the relationships between core formation, reverse 
transcription, and infectivity of ALLINI-treated particles, and conclude from dose-response 
curves that inhibition of particle maturation is the process that underlies the potencies of two 
representative ALLINI compounds. Using cryo-ET, we found that, in addition to affecting vRNP 
incorporation into the mature core, ALLINIs reduced by a factor of approximately five the 
efficiency with which conical cores are formed. To demonstrate that the eccentric condensate is 
indeed composed of NC and RNA, we applied tomo-bubblegram imaging, a novel technique that 
takes advantage of the acute sensitivity of NC protein to electron irradiation expressed in the 
generation of bubbles as radiation damage products. The same approach confirmed that NC – 
and by inference, the vRNP – is present inside wildtype cores, predominantly at the wide end; 
and that NC lines the inner part of the thick-walled Gag shell in immature virions. Using Vpr-IN 
to functionally transcomplement particles that lack IN (∆IN), we also show that IN promotes 
conical core formation and HIV-1 infectivity in parallel. Furthermore, we implicate vRNA as a 
necessary component for ALLINI action during virus production. Together, these results imply 
that IN has a direct role in nucleating the assembly of conical cores and the incorporation of the 
vRNP into the mature core; and that ALLINI treatment effectively subverts this role(s) of IN 
during HIV-1 particle maturation. 
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Results 
 
Inhibition of virion maturation underlies ALLINI potency  
ALLINIs have been reported to inhibit multiple aspects of HIV-1 replication including 
virion maturation, reverse transcription, nuclear import, and integration (see Introduction), 
suggesting that it may be the combination of multiple inhibitory processes that underlies ALLINI 
potency. An alternative scenario is that inhibition may be due to a single dominant or bottleneck 
step, which in this case would be particle maturation, as it is the first step inhibited from the 
perspective of the virus producer cell. To investigate this possibility, we compiled dose-response 
curves measuring the first two steps affected by ALLINIs - maturation and reverse transcription - 
and compared them to overall antiviral activity as assessed by the expression of the luciferase 
reporter gene in cells infected with drug-treated HIV-Luc particles. If maturation is a bottleneck 
step, we anticipated that its inhibition would equate with antiviral potency. If inhibition of 
multiple steps is involved, then the maturation and reverse transcription inhibitory curves would 
individually be less potent than overall antiviral activity.    
HIV-Luc was produced in the presence of two representative ALLINI compounds, BI-D, 
with an EC50 for inhibition of HIV-1 infection of 89 nM, and BIB-2 (also known as ALLINI-2), 
with an EC50 of 630 nM (236, 237) (Figure 1-6), at varying EC50 doses (1X, 2X, 4X, and 8X). 
TEM analysis of virus made in the presence of solvent control DMSO revealed that 87 ± 2% of 
these particles harbored mature cores with internal density. This value decreased by ~ 50% when 
virus was produced with unit EC50 concentrations of BI-D or BIB-2, with accompanying 
increases in particles containing eccentric condensates (Figure 3-1A). Higher doses of each 
compound further reduced the fraction of mature cores and increased the fraction  
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Figure 3-1. Inhibition of virion maturation underlies ALLINI potency 
(A) Left, quantitation of core morphotype frequencies (average ± SD for 2 independent 
experiments) for sets of 100 counted HIV-Luc particles. Right, representative TEM images of 
mature, eccentric, and immature virions produced in these experiments. (B) Quantitation of late 
reverse transcription product formation from infections initiated with samples shown in panel A. 
(C) Antiviral activity as assessed by bulk luciferase output. Error bars in panels B and C are the 
variation obtained from three independent experiments. 
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of eccentric condensate-containing particles. The reverse transcription activity and infectivity 
(luciferase activity) of the particles were measured in SupT1 cells infected with equal amounts of 
virus, as quantitated by their CA/p24 content. By comparing the results of Figure 3-1A & B, we 
determined that the effect of drug treatment on reverse transcription activity closely paralleled 
the inhibition of mature core formation (Pearson correlation coefficient r2=0.998 for the two sets 
of dose-response curves; P <0.001). Inhibition of reverse transcription moreover paralleled 
overall antiviral activity (Figure 3-1C; Pearson correlation coefficient r2=0.903 for these two 
datasets; P <0.001).  
 
ALLINI treatment affects conical core assembly in addition to vRNP incorporation into the 
mature core 
Having determined that the antiviral activity of two independently tested, representative 
ALLINIs correlates with their inhibition of particle maturation, we performed cryo-ET to further 
probe the antiviral phenotype. Virions produced with full inhibitory ALLINI concentrations 
(10X EC50 for BIB-2; 10-100X EC50 for BI-D; Figure 3-1C) were classified according to core 
morphology (conical – e.g. Figure 3-2A, B; non-conical – e.g. Fig. 3-2C, D; or no core), and the 
presence (Figure 3-2B, D) or absence (Figure 3-2A, C) of an eccentric condensate. The eccentric 
condensate was previously observed by TEM as a compact, darkly staining body common to 
class II IN mutant viruses (146, 233, 284, 291) and ALLINI-treated virions (228, 233, 284). We 
used cryo-ET to extend these observations (Figure 3-2B, D). Their compactness and density 
distinguish condensates from the other material that typically occupies the space between the 
core and the viral envelope, which we take to be mostly non-polymerized CA (292, 293) and 
host cell proteins (294). In BI-D-treated particles, the eccentric condensates have ellipsoidal 
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Figure 3-2. Classification of HIV-1 particles observed by cryo-ET 
(A-D) Tomographic central slices of representative HIV-1 virions classified according to core 
morphology (conical or non-conical) and the presence or absence of an eccentric condensate  
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Continued legend for Figure 3-2 
(white arrows). Eccentric condensates appear denser than the material lying between the core and 
the envelope in particles that lack an eccentric condensate. The cores of virions that have an  
eccentric condensate are relatively empty (e.g. panel B). Bar, 50 nm. (E) Percentages of HIV-1 
virions classified according to their core morphology (conical, non-conical, or no core) and 
presence or absence of an eccentric condensate. The majority species for each sample is given in 
bold font. According to the chi-square test, significant differences with P-values < 0.00001 were 
found for comparisons between WT and BIB-2 and between WT and V165A. The difference 
between WT and BI-D had a P-value of 0.013, whereas the differences between V165A and BI-
D or BIB-II were not significant, with P-values > 0.26. The Chi-square test was used to test for 
equal distribution of compartmentalized data, but should not be used if more of 20% of the bins 
contain fewer than 5 counts. Therefore, immature virions were not taken into account and virions 
with no cores were considered a single category, independent of the presence or absence of an 
eccentric condensate. 
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shapes with major and minor axes of 58 ± 12 nm and 37 ± 12 nm (n=93), respectively; those 
present in particles treated with BIB-2 or untreated V165A particles, which was utilized as a 
class II IN mutant control (233), were similar in size. The incidence of these morphological 
classes is summarized in Figure 3-2E. Eccentric condensates are relatively rare (~12%) in WT 
virions but present in ~75% of particles treated with BI-D or BIB-2, or with the V165A IN 
mutation. We observed no virions with more than one eccentric condensate.  
As in earlier studies by cryo-ET (e.g. (59, 279, 287)), most WT virions (~77%) were 
found to have closed conical cores with internal density (Figure 3-2A), noting that the 
tomograms would not detect small holes if present (295). Most of the eccentric condensate-
containing virions from BI-D or BIB-2 treatment or the V165A IN mutant also have a core 
(Figure 3-2E), but there are two striking differences between these cores and WT cores. First, 
they have a much higher incidence of non-conical cores than with WT (the ratios of non-conical 
to conical cores were 1.8 : 1 for BI-D, 0.9 : 1 for BIB-2, and 1.6 : 1 for V165A, as compared to 
1 : 7.2 for WT). Thus, there is marked impairment of capsid morphogenesis. Second, V165A/BI-
D/BIB-2 conical cores are relatively empty, as exemplified by comparing Figure 3-2A and B. 
With WT cores, internal material is generally taken to consist mainly of the vRNP, although this 
assignment has not been formally demonstrated and is addressed further below. While conical 
V165A/BI-D/BIB-2 cores have less internal content than the WT ones, they tend to have some 
internal material (e.g. Figure 3-2D). With this caveat, we estimate that ~50% of them have little 
or no content vs. 3% for the WT virions. These data suggest that V165A/BI-D/BIB-2 virions are 
deficient in capsid morphogenesis in addition to incorporation of the vRNP into the mature core.  
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Bubblegrams detect radiation-sensitive material in filled cores and eccentric condensates 
It is plausible that eccentric condensates represent NC-vRNA complexes that failed to be 
incorporated into the mature core. We obtained supporting evidence for this hypothesis by means 
of a labeling technique called “bubblegram imaging” (296, 297). Vitrified samples imaged in an 
electron microscope undergo progressive damage by electron irradiation. This damage is initially 
expressed as a 'smearing' of the macromolecular density, and for this reason the electron dose is 
kept as low as possible during imaging (298). When proteinaceous specimens are subjected to 
relatively high levels of electron irradiation in cryo-EM – perhaps 10-fold higher than the dose 
used in a typical imaging experiment - bubbles of hydrogen gas are generated (299, 300), which 
are readily visible due to their low density. Different proteins have different bubbling thresholds 
(N,C., Weimin Wu, Anastasia Aksyuk, J.F. & A.C.S., unpublished observations). Moreover, 
proteins intercalated in DNA bubble relatively early because the densely packed DNA impedes 
the diffusion of radiation products from their sites of origin, accelerating their build-up to a 
critical concentration for bubbling. Hypothesizing that compact NC-vRNA condensates may 
have distinctive bubbling behavior, we subjected HIV-1 virions to bubblegram imaging. In 
“dose-series” micrographs (not shown), small bubbles first appeared after a cumulative dose of 
160 - 200 e-/Å2 and grew in size and number with subsequent exposures. The bubbles co-
projected with filled cores and eccentric condensates, and the two structures appeared to have the 
same bubbling threshold, although in some micrographs the boundaries of these structures were 
difficult to discern. However, we could not rule out that the bubbles may not be inside these 
structures but coincidentally lie along the same line-of-sight.  
 Aiming to eliminate the ambiguity of co-projection, we extended the bubblegram method 
to 3D imaging by electron tomography. We call this method “tomo-bubblegram imaging”. First, 
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a regular tilt-series is collected from an area of interest and a tomogram is calculated. This 
involves a total dose of ~75 e-/Å2, which is below the bubbling threshold for HIV-1. Second, an 
untilted dose-series is performed, stopping after the first small bubbles begin to develop (another 
~70 e-/Å2). Third, after waiting ~2 h to allow radiation products to dissipate, a second tilt series 
is recorded (~70 e-/Å2) during which larger bubbles appear in the “primed” specimen. These 
bubbles are visualized in the corresponding tomogram – the “tomo-bubblegram”. Finally, 
comparing the first tomogram (the “before” state with the virions in a close-to-native state) and 
the second one (the “after” state) allows the sites in which the bubbles nucleated to be mapped in 
three dimensions. As illustrated in Figure 3-3 and Table 3-1 the bubbles specifically label the 
core interiors in WT virions, predominantly towards the wide end of the core. They also label the 
eccentric condensates of V165A and BI-D/BIB-2 virions. Of note, bubbles were never seen only 
inside cores (i.e. outside the condensates) of V165A or BI-D/BIB-2 virions that also contained 
eccentric condensates: in these particles, either bubbles were observed only in the condensate 
(~80% of the condensate-containing particles) or in both the condensate and the core (~20%). In 
summary, we found that the WT conical core contents and eccentric condensates are more prone 
to bubbling than the other components of the virion (CA protein, MA protein, envelope 
glycoprotein) and they are indistinguishable in this respect. In turn, this correlation strongly 
supports the idea that they are chemically the same and are indeed NC-vRNA complexes. 
 
Bubbles label NC-RNA in immature virions 
To further investigate which component of HIV-1 virions is bubbling, we examined immature 
(PR-defective. i.e. PR–) virions in which, in the absence of proteolysis, the Gag and Gag-Pol 
domains are radially ordered, with MA in contact with the viral membrane, and CA and   
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Figure 3-3. Tomo-bubblegrams of HIV-1 particles 
(A-X) Each pair of panels shows a central section from an initial tomogram (left) and the 
corresponding section from the tomo-bubblegram (right). The types of virions analyzed are 
labeled on the left side of each block. BIB-2 (10X) and BI-D (10X EC50 for panels G, I, and L; 
100X EC50 for panels H, J, and K) were used at full inhibitory concentration. Particles with 
conical cores are framed in red and those with non-conical cores in blue; particles lacking 
eccentric condensates are framed with continuous lines and particles that have eccentric 
condensates, with dashed lines. Bar, 50 nm. 
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Table 3-1. Tomo-bubblegram labeling of HIV-1 virions 
	  
 
aThe data are shown as percentages of virions with bubbles either inside the core, outside the core, or both.  
 Conical core, no condensate 
Non-conical core, no 
condensate 
Condensate with core (conical or 
non-conical) 
Bubbles: Inside core 
Outside 
core Both 
Inside 
core 
Outside 
core Both 
Outside 
condensate 
Inside 
condensate Both 
WT 
(N=78) 
55 0 19 1 3 3 4 4 9 
BI-D 
(N=72) 
7 0 7 1 1 6 0 56 21 
BIB-2 
(N=64) 
8 0 0 0 3 0 0 77 12 
V165A 
(N=88) 
3 0 2 6 0 2 0 67 18 
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NC/vRNA arranged in successive concentric layers. PR– virions (HIV-1NL4-3 with the D25A 
inactivating mutation in the PR active site) exhibited a similar bubbling threshold as WT virions, 
although the bubbles appeared in a different location, i.e., within the Gag shell (Figure 3-4Ai, ii). 
Radially, these bubbles are centered at ~15 nm (average 15 ± 5 nm; n=333) in from the middle of 
the viral envelope, a position that corresponds to the interface between the CA and NC+vRNA 
layers (Figure 3-5). In the other two dimensions of the Gag lattice, we did not find a preference 
for bubbling in any particular location. 
Next, immature virions in which vRNA and NC were respectively eliminated from Gag 
virus-like particles (VLPs) were analyzed to test for the relative contributions of these two 
components to bubbling phenomena. A VLP construct that lacked the vRNA ψ region (301) 
reduced the packaging of vRNA relative to total virion RNA by ~20,000-fold (Figure 3-4B, C). 
Gag/ψ-minus particles bubbled in the same locations as immature (PR–) virions, thus showing 
that vRNA is not needed for bubbling (Figure 3-4Aiii, iv). We do, however, note that the 
bubbling appeared to be slightly reduced with this construct (16 ± 10 bubbles/virion in Gag/ψ-
minus particles vs. 27 ± 15 bubbles/virion in PR– particles – Table 3-2; the differences are 
significant at p < 0.01 according to the two-tailed student T-test). The difference, such as it is, 
might arise from the ~2.5-fold reduction in overall RNA content in Gag/ψ-minus particles, as the 
RNA may impede the dispersal of hydrogen gas generated from NC. To eliminate NC but 
nevertheless retain structurally similar particles, we used a construct in which the NC domain of 
Gag was replaced by a leucine zipper (35), in which Gag otherwise retains its immature 
conformation (302). The Gag-LeuZip VLPs yielded almost no bubbles (Figure 3-4Av, vi; 0.3 
bubbles/virion vs. 16 bubbles per Gag/ψ-minus VLP at the same electron doses), and ~94% of  
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Figure 3-4. Tomo-bubblegrams of immature HIV-1 particles 
(A) (i-vi) Central tomographic sections (left) and corresponding tomo-bubblegram sections 
(right). The diagrams on the left side of the figure convey the composition of each sample. PR–  
particles contain the Gag and Gag-Pol polyproteins that includes NC and incorporates vRNA. 
The virions are immature due to the inactivating D25A mutation in the PR active site. Gag/ψ-
minus particles are also immature, and additionally their RNA lacks the ψ region and therefore 
vRNA is not incorporated into particles. The Gag-LeuZip particles replace NC with a leucine 
zipper; these particles lack NC and vRNA. Bar, 50 nm. (B) Total virion RNA from the particles 
described in A. RNA concentration was normalized to the Gag signal obtained from anti-p24 
western blots of multiple input volumes. Shown are average (± SD) of total RNA (ng) 
standardized by Gag signal for 4 independent experiments, reported as percentage of PR-. (C) 
RNA from B was utilized to determine the copy number of vRNA. Values, reported as a 
percentage of PR-, are the average (± SD) for 4 independent experiments.  
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Figure 3-5. Locations of bubbles in PR- virions 
(A) Cryo-ET central slice of an immature PR– particle. (B and C) The tomo-bubblegram section 
corresponding to panel A. In C, bubbles are marked with red circles. (D) Surface rendering of a 
cutaway slice of the particle shown in panels A-C. Most of the bubbles (white) are located 
between the CA layer (green) and the NC-vRNA layer (yellow). The viral envelope is in cyan 
and the internal contents in red. Bar, 50 nm. (E) Radial density profile of subtomogram 
averaged Gag from immature virions (from (287)). (F) Histogram of the distance from the 
center of the bubbles to the center of the viral envelope (membrane + MA). 
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Table 3-2. Bubbles in three kinds of PR- HIV-1 particles 
 
 
1 For PR– and Gag/ψ-minus VLPs, the bubbles from 29 and 31 virions were counted respectively. For the Gag-LeuZip, bubbles from 
all particles imaged were counted. 
  
 
 
 
# of 
tomograms 
Total avg. 
dose (e-/Å2) # virions 
# bubbles 
/virion1 
% of virions 
with 2 or 
more 
bubbles 1 
% of virions 
with 1 or no 
bubbles 1 
PR– 3 215 65 27 ± 15 100 0 
Gag/ψ-minus 4 221 53 16 ± 10 100 0 
Gag-LeuZip 4 228 53 0.3 ± 0.6 6 94 
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these particles had 0 or 1 bubble (vs. 100% of the control particles that each had two or more 
bubbles; Table 3-2). The relative levels of total RNA and vRNA in Gag-LeuZip VLPs were 
similar to those in Gag/ψ-minus VLPs (Figure 3-4B, C), though we do note that an earlier study 
failed to detect tangible RNA levels in Gag-LeuZip VLPs (35). Nevertheless, we conclude that, 
apart from a very low background of bubbles from other sources (as illustrated in Figure 3-4Av, 
vi), NC protein is the bubbling component.  
 
Purified NC exhibits similar bubbling behavior to that observed in mature and immature 
virions 
Identification of NC protein as the component responsible for bubbling in both mature 
WT and IN mutant/ALLINI-treated virions and in immature virions led to the prediction that NC 
protein should also bubble provided that it is suitably concentrated. To test this hypothesis, we 
examined aggregates of purified NC. Aggregates were similar in diameter to eccentric 
condensates (average 51 ± 20 nm, n=69, vs. 48 ± 9 nm, n=93), and were found to have a similar 
bubbling threshold to that of eccentric condensates (average, 154 ± 57 e-/Å2, n=69 vs. 165 ± 42 
e-/Å2, n=69). Their bubbling threshold was somewhat dependent on size, with larger aggregates 
bubbling earlier than smaller ones (Figure 3-6). This is consistent with the greater abundance of 
NC in larger aggregates providing a richer source of hydrogen gas as a radiation product. 
Strikingly, bubbling started in the middle of these aggregates and then spread outwards, 
consistent with the outer layers of molecules impeding the outward diffusion of the gas. Taken 
together, these observations provide strong evidence that the bubbling component in HIV-1 
virions is NC protein, and therefore confirm that ALLINI treatment affects incorporation of the 
vRNP into the core. 
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Figure 3-6. Bubblegram imaging of purified NC protein 
 (A-E) Cryo-EM dose series of five NC aggregates of different sizes. The images in which 
bubbles first appear are labeled with a white asterisk in each case (although NC is formally 
soluble, small aggregates of suitable size were consistently found on EM grids). Bar, 50 nm. (F) 
Plot of the diameters of NC aggregates vs. the cumulative electron dose at which they started 
bubbling. Points corresponding to the aggregates from panels A-E are shown in red. While the 
data exhibit some stochastic variability in bubbling threshold, there is a clear trend towards 
larger aggregates requiring less electron radiation to initiate bubbling. A linear fit is shown for 
reference (red line).  
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ALLINI-induced eccentric condensate formation requires vRNA  
To address whether ALLINI-mediated impairment of vRNP incorporation into the mature 
core is dependent upon the species of RNA within the virus, we co-transfected pHI-Luc, which 
expresses a minimal HIV-1 transfer vector that harbors ~45% of the full-length vRNA genome, 
with pHP-dl-N/A that expresses the Gag and Pol proteins required to package HI-Luc vRNA in 
trans. As a transfection control for pHI-Luc, we utilized the promoter-less pGL3-basic (GL3-B) 
construct that carries the luciferase gene but lacks HIV-1-related sequences and the capacity to 
express RNA. Total RNA levels of pelleted virions nevertheless did not vary significantly 
between those made in the presence of pHI-Luc or GL3-B, although, as expected, the HIV-1 
genome was selectively incorporated into HI-Luc particles (Figure 3-7A, B). We also note that 
HI-Luc total and vRNA levels were similar to those of the HIV-Luc virions characterized in 
Figure 3-1. TEM revealed that ~30% of HI-Luc viruses harbored WT-like conical cores, ~22% 
harbored cores as well as eccentric aggregates, ~25% had a previously unseen morphology 
wherein dual electron density (dual ED) appeared both inside and outside the core, ~15% had 
empty cores, and ~15% contained immature-like spherical shells (Figure 3-7C). The baseline 
phenotype of virions made in the presence of GL3-B did not differ dramatically from that of 
virions that harbored HI-Luc vRNA (Figure 3-7C). As expected, BI-D treatment increased the 
frequency of HI-Luc virions with eccentric aggregates (~60%), with accompanying decreases in 
mature (~5%) and dual ED (~1%) cores. By contrast, the fraction of virions with eccentric 
aggregates did not significantly change when sham virus made in the presence of GL3-B was 
treated with BI-D (Figure 3-7C).  
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Figure 3-7. Viral RNA requirement for eccentric condensate formation 
(A) Total RNA (ng) of concentrated virion preparations. RNA concentration was standardized by 
the p24 signal obtained from western blots of multiple input volumes. Shown are averages (± 
SD) from 4 independent experiments reported as percentages of untreated HIV-Luc virions. (B) 
Average (± SD) copies of vRNA per ng total RNA (n=4) determined for the samples described in 
A. (C) Left, core morphology frequencies in sets of 100 counted virions (average ± SD) from two 
independent isolates of particles prepared as described in A. **, P < 0.01; n.s., not significant  (P 
= 0.37). Right, representative images of the mature, eccentric, dual electron density (ED), empty, 
and immature virions observed in these experiments.  
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Partial recovery of WT core formation by IN in trans 
TEM classification of ∆IN virions revealed that the majority (~61%) contained eccentric 
condensates while ~9% harbored WT-like conical cores and ~30% were immature (233). To 
assess the role of IN in HIV-1 maturation and the impact of ALLINI treatment on this role, ∆IN 
virions were functionally trans-complemented by IN fused to the viral accessory protein Vpr. 
INH171T, which confers ~44-fold resistance to BI-D (226), was utilized as a control. Although 
class II IN mutations such as ∆IN can impede CA/p24 release in a cell type-dependent manner 
(158, 250), the ∆IN virus used here yielded supernatant p24 values similar to the WT control 
virus (233). Vpr-IN boosted the infectivity of the highly defective ∆IN virions ~100-fold, to a 
level equal to ~5-10% of the infectivity of the parental HIV-Luc virus (Figure 3-8A). As 
expected (233), a 10X EC50 dose of BI-D abolished the infectivity of ∆IN virions trans-
complemented with Vpr-INWT but not with Vpr-INH171T. Concomitant with the gain in infectivity, 
the incidence of conical cores rose from ~9% to ~30% upon Vpr-IN transcomplementation 
(Figure 3-8B). With Vpr-INWT, ALLINI treatment restored this phenotype to the non-
complemented ∆IN value of ~9%, whereas virions trans-complemented by Vpr-INH171T harbored 
~30% mature cores, regardless of ALLINI treatment.  
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Figure 3-8. IN in trans stimulates WT core formation in ∆IN virions 
(A) Infectivity of HIV-Luc.∆IN transcomplemented with Vpr-INWT or Vpr-INH171T made in the 
presence of BI-D or DMSO. Values were normalized to control HIV-Luc virus constructed in the 
presence of DMSO. (B) Upper, quantitation of core morphology frequencies of 100 counted 
virions (the ∆IN mutation yields more immature particles than does other class II (e.g., missense) 
mutations (233, 303)). Shown are average ± SD for 2 independent experiments for the 
transcomplemented preparations described in A. Lower, representative images of the mature, 
eccentric, and immature virions observed within experiments.  
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Discussion 
In this study we have utilized the recently discovered antiviral activity of ALLINIs to 
assess the role of IN in HIV-1 maturation. Of virions assembled in ALLINI-treated cells, the 
fraction that acquires a closed conical capsid (taken to be a requirement for infectivity - (82)) is 
markedly reduced. Many of these capsids are malformed. Moreover, in most of these virions, the 
vRNP is not incorporated into the mature core but remains outside the capsid as an “eccentric 
condensate” – even if a closed conical capsid is assembled. These phenotypes are reproduced by 
various class II IN mutations, including the V165A point mutation or IN deletion. IN supplied in 
trans partially rescued the fraction of ∆IN virions that harbored WT cores with internal electron 
density, a recovery that could be abolished by ALLINI treatment (Figure 3-8B). As vRNA was 
required for ALLINI-induced eccentric condensate formation, we suggest a model wherein 
disruption of an IN-vRNA interaction, either by genetic or pharmacological means, results in the 
inability to properly incorporate the vRNP into the capsid during HIV-1 core morphogenesis. 
 
ALLINI antiviral activity is due to inhibition of HIV-1 particle maturation 
ALLINIs have been shown to inhibit several steps of the HIV-1 replication cycle (see 
Introduction). However, it has been unclear whether inhibition of multiple steps combines to 
determine drug potency, or whether ALLINs inhibit a single bottleneck step in the replication 
cycle. To address this issue we correlated dose-response curves from inhibiting maturation and 
reverse transcription – the first two steps that are inhibited from the perspective of the drug-
treated virus-producer cells – to overall antiviral activity. As all three curves (percentage of 
mature cores, reverse transcription activity, infectivity) effectively superposed with highly 
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significant correlations for two representative inhibitors, we conclude that inhibition of HIV-1 
maturation determines the antiviral potency of these compounds. 
 Similar to PIs (245), ALLINIs display relatively steep dose response curves (232, 233). 
Two mutually non-exclusive models for this behavior posit that such compounds inhibit multiple 
copies of the drug target at the relevant step of the replication cycle (245) or that they inhibit 
multiple steps in the replication cycle (304). Whereas inhibition of multiple replication steps 
appears to underlie the cooperative behavior of PIs (304), we conclude from our data that 
ALLINIs mainly if not exclusively target IN during HIV-1 maturation and, by inference, that 
multiple copies of IN, if not the full virion complement of the protein, are affected. We 
accordingly note similar slopes of BI-D dose response curves for stimulation of purified IN 
multimerization in vitro (m ~2) and inhibition of HIV-1 replication (m ~2.8) (233). 
 
Tomo-bubblegram imaging labels NC-containing complexes in 3D 
Cryo-ET and tomo-bubblegram imaging have given a clearer account of the substructure 
of HIV-1 virions whose maturation was subverted by a class II mutation in IN or by ALLINI 
treatment. First, we confirmed earlier TEM data (228, 233, 284, 286) that ALLINI treatment 
yields a high proportion of virions with eccentric condensates. This property reoccurs in the class 
II IN mutant control virus. Second, being able to visualize the 3D structures of complete virions 
in greater detail, we additionally found an adverse effect of the V165A mutation and ALLINIs 
on capsid morphogenesis. 
We now consider the density inside conical capsids of mature WT virions. This density 
has been interpreted as the vRNP, composed primarily of NC and vRNA. The vRNP also 
contains the RT and IN enzymes and some other viral and host cell components (82, 305-307). 
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Serendipitously, NC turned out to be highly susceptible to irradiation-induced bubbling and we 
exploited this property to demonstrate that NC is indeed a major internal component of WT 
cores; moreover, the NC is primarily at the wide end of the core (see Figure 3-3A-F; also (58)). 
Because few bubbles are seen elsewhere in virions, it seems that most if not all of the NC protein 
goes into the core. These data directly support earlier evidence that most or all of NC is in the 
core, whereby the ratio of NC to CA was found to be significantly higher in isolated cores than 
in virions (308), in keeping with the property that only about half of the CA present in an 
immature virion assembles into a mature capsid (292, 293). Similarly, our tomo-bubblegrams 
have shown that eccentric condensates are rich in NC, with few bubbles seen anywhere else in 
condensate-containing virions.  
The typical dimensions of the material enclosed in the wide end of a WT core are similar 
to those of an eccentric condensate. It appears therefore that when NC and the attached genomes 
are released from the Gag shell in a maturing virion, they condense into one or the other of these 
aggregates. A heuristic calculation supports this inference. If one takes an eccentric condensate 
to have major axes of 55 x 55 x 35 nm (see above), its volume is ~55,000 nm3.  Assuming ~50% 
of this volume to be occupied by protein (a value typical for a protein crystal) and a protein 
density of 0.78 kDa/nm3, a mass of 21.5 MDa results. Alternatively, an NC copy number of 
~2000 - 2500 per virion (251) and a subunit mass of 7.2 kDa gives a total mass of ~14 - 18 MDa. 
Therefore, the eccentric condensates are large enough to account for all of the NC plus the two 
copies of the vRNA genome, which remain associated with NC after virion maturation (24, 309). 
Our analysis also shows that ~12% of WT virions contain eccentric condensate: of these, 75% 
have conical cores and 25% have non-conical cores. The existence of such particles demonstrates 
miscarried vRNP incorporation into mature cores under the otherwise unperturbed WT situation 
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of HIV-1 clade B strain NL4-3 assembly from transfected HEK293T cells. Additional work with 
other viral clades and cell types would be needed to discern how broadly applicable this 
observation may be.  
 
Implications for core assembly 
In order to assemble a core, PR must dissect Gag and Gag-Pol, with their component 
domains being separated in a tightly regulated cleavage sequence (310). Finally, CA is released 
from the maturing Gag shell into a pool whence it assembles to form the mature core, leaving 
about 50% unassembled (59, 288, 292, 293). During core assembly, NC together with the vRNA 
and IN and RT enzymes becomes situated into the mature core (see above).  
Several models have been proposed for how capsid assembly takes place (59, 279). They 
differ on whether assembly starts at the wide end (279) or the narrow end (59) and are couched 
primarily in terms of self-assembly properties attributed to CA protein, since conical capsids 
similar to the ones observed inside HIV-1 virions can be assembled from purified components in 
vitro (311). It has also been suggested that the vRNP may help to nucleate assembly (58, 60, 
279), ensuring its incorporation into the capsid, and that MA or the inner surface of the viral 
membrane could direct the closure of the core (59). A related idea for coupling capsid assembly 
with vRNA packaging was advanced for Rous sarcoma virus in that some unprocessed or 
incompletely processed copies of Gag in the Gag shell may form a nucleation complex that binds 
via the NC moieties to a genomic packaging site and, via the CA moieties, nucleates outgrowth 
of the capsid shell (312). Although IN has been implicated in regulating PR activity during HIV-
1 assembly and particle release (158), a role for the viral enzyme in core morphogenesis has not 
been proposed. Based on our data, we propose an active role for IN in initiating vRNP 
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incorporation into the mature core, which then nucleates capsid formation around the enclosed 
vRNA-NC complex (Figure 3-9). This scenario could in theory apply to pre-cleavage IN as a 
domain of Gag-Pol or post-cleavage IN that has remained in essentially the same position. 
Supporting a model for an IN-vRNA interaction(s) in core morphogenesis, our data reveal a role 
for vRNA in ALLINI-induced eccentric condensate formation (Figure 3-7) and high affinity 
binding of purified HIV-1 IN to RNA has been observed in vitro (161). Linkage between IN and 
CA changes has moreover been noted among strains in drug-naive and drug-experienced AIDS 
patients (313), indicating a potential biological role for an IN-CA interaction. IN-RNA and IN-
CA interactions are two avenues that we are currently pursuing to investigate the mechanistic 
basis of IN in HIV-1 core formation and vRNP incorporation into the mature core. 
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Figure 3-9 Model for the role of IN in during HIV-1 maturation 
Maturation starts with activation of the PR and dissection of the Gag and Gag-Pol polyproteins 
and release of the vRNP/NC from the Gag shell. The key element of this model is that it 
envisages a molecular complex containing one or several copies of Gag-Pol that initiates both 
assembly of the capsid by an outgrowth of CA subunits and packaging of the vRNA through 
binding to IN or to RT as conformationally influenced by IN. The cartoon shows RT and IN 
associated with the eccentric condensate for which there is currently no evidence although they 
do remain, mostly or totally, inside the wild-type capsid (307). A variant of this model in the 
Rous sarcoma virus system envisages participation of the cytoplasmic domain of Env (312). The 
virion and core also contain other components (e.g. Vpr in the core; some host proteins 
somewhere in the virion), which are not shown.  
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Materials and Methods 
Plasmids and antivirals 
HIV-1NL4-3 carrying WT IN was expressed from pNL43/Xmal (265) whereas the V165A 
IN mutant was expressed from pNL43/XmaI.V165A (29) (246). Single-round derivatives HIV-
Luc and HIV-Luc.ΔIN were expressed from pNLX.Luc.R- (250) and pNLX.Luc.R-.ΔIN (233), 
respectively. The D25A mutation in PR was introduced into pNL43/XmaI using PCR-directed 
mutagenesis. Gag/ψ-minus VLPs were expressed from pRR359 (301) whereas Gag-LeuZip was 
expressed from pRR546 (35). HIV-1-based pHP-dI-N/A packaging plasmid (314) was 
cotransfected with pHI-Luc transfer vector (315) or pGL3-Basic control plasmid (Promega). Vpr 
fused to the IN protein from HIV-1SG3 (WT or H171T) was expressed from pRL2PVpr-IN (233, 
268) whereas the VSV-G glycoprotein was expressed using pCG-VSV-G (250). BI-D and BIB-2 
were synthesized as described (236, 237). EFV was obtained from the National Institutes of 
Health AIDS Research and Reference Reagent Program. 
 
Cells, viruses, and antiviral assays 
Transformed HEK293T cells (American Type Tissue Collection item number CRL-3216) 
were grown in Dulbecco’s modified Eagle medium while human SupT1 T cells (NIH AAARP 
item number 100) were maintained in RPMI medium 1640, both supplemented to contain 10% 
(vol/vol) fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin. HIV-Luc was 
produced by cotransfecting HEK293T cells (8 x 105) with 3.5 µg pNLX.Luc.R- and 0.35 µg 
pCG-VSV-G using PolyJet transfection reagent (SignaGen Laboratories). HIV-1NLX.Luc.R-
ΔIN was transcomplemented with Vpr-IN by cotransfecting HEK293T cells (3 x 106) with 4.5 
µg pNLX.Luc.R-.ΔIN, 1.25 µg pRL2P-Vpr-IN containing WT or H171T IN, and 0.5 µg pCG-
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VSV-G. DMSO or ALLINIs were added with fresh media at ~17- 20 h post transfection, and cell 
supernatants were collected 24 h later. Cell-free virus concentration, typically 500-1000 ng/mL, 
was determined using a commercial p24 ELISA kit (Advanced Biosciences Laboratories). For 
Vpr-IN complementation experiments, SupT1 cells were infected in quadruplicate with 5 ng/mL 
p24. Luciferase values, expressed as relative light units, were determined 48 h postinfection. 
 
DNA analysis and quantitative PCR 
SupT1 cells (2 x 106) infected with DNase-treated (1 h at 37 °C) HIV-Luc (50 ng 
p24/mL) for 2 h were washed and split into two samples. DNA was isolated from one set of 
samples 5 h later using the DNeasy blood and tissue kit (Qiagen). The other set of samples was 
seeded in quadruplicate in 96-well plates, and luciferase activity was determined 48 h from the 
start of infection. Duplicate PCRs containing 50 ng DNA, 0.2 µM primers (AE2963/AE4422), 
0.1 µM probe (AE2965), and 1X QuantiText Probe PCR Master Mix were incubated at 50 °C for 
2 min and 95 °C for 15 min, followed by 40 cycles of 94 °C for 15 s, 59 °C for 30 s, and 72 °C 
for 30 s (116). Standards were prepared by end-point diluting pNLX.Luc.R- into DNA from 
uninfected cells. To account for potential residual plasmid carryover from transfection, parallel 
infections were preformed in the presence of 10 µM EFV, and the values obtained from these 
PCR assays were subtracted from the experimental samples. 
 
 RNA isolation and analysis 
Total RNA was extracted from concentrated virus preparations after a 30 min incubation 
with 0.05 µg/mL proteinase K (Life Technologies) and 0.40% SDS at 56 ºC. Following phenol 
chloroform extraction, RNA was precipitated using isopropanol and GenElute-LPA (Sigma-
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Aldrich) as carrier. RNA concentration was determined by the Ribogreen (Invitrogen) assay, 
which was completed according to the manufacturer’s instructions. PCRs to determine vRNA 
copy number per ng total RNA were completed as previously described (233), utilizing 2 µL of 
purified RNA and primer sets AE2963/AE2964 for Figure 3-7 (excluding HIV-Luc) and 
AE2961/AE4422 for Figure 3-8 samples and HIV-Luc. 
 
TEM 
Viruses produced from transfected HEK293T cells were pelleted at 30,000 rpm at 4°C 
for 1.5 h using a Beckman SW41 rotor. Pelleted virus was resuspended in a small volume of 
phosphate-buffered saline. An equal volume of 4% EM-grade paraformaldehyde (Electron 
Microscopy Sciences) was added and samples were incubated at 4 °C before embedding in epon 
resin. Thin (75-100 nm) sections were applied to 200-mesh carbon-coated copper grids, stained 
with 0.2% lead citrate, and observed using either a Tecnai-12 (FEI) or JEOL 1200EX 
microscope equipped with a Gatan or AMT 2k CCD camera, respectively. Images were captured 
at 37,500X magnification and were visually scanned to count 100 viral particles per preparation. 
 
Cryo-ET 
HIV-1 carrying the V165A mutation, WT virons produced with the indicated 
concentration of ALLINIs or DMSO control, PR– virions, Gag/ψ-minus VLPs, and Gag-LeuZip 
VLPs were pelleted as described above and were imaged by cryo-ET as described previously 
(316). In brief, purified fixed virus was mixed (2:1) with a suspension of colloidal gold particles 
(Electron Microscopy Sciences), applied to Quantifoil R2/2 holey carbon grids (Structure Probe, 
Inc.), and plunge-frozen in a Vitrobot (FEI). For data acquisition, grids were transferred to a 
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cryoholder (type 626; Gatan), and single-axis tilt series were recorded on a Tecnai-12 electron 
microscope equipped with an energy filter (GIF 2002; Gatan) operated at 120 keV in zero-loss 
mode with an energy slit width of 20 eV. Images were acquired on a 2,048- by 2,048-pixel CCD 
camera (Gatan) using SerialEM (317). Tilt-series projections were acquired at 2º intervals from ~ 
-66º to ~ 66º, at 38,500x magnification (0.78-nm/pixel) and a defocus of -4 µm. The electron 
dose per projection was ~1.1 e-/Å2, giving a total cumulative dose of ~75 e-/Å2. Tilt209 series 
were reconstructed using the Bsoft package (318), and virions were extracted as subtomograms 
and denoised by 20 iterations of anisotropic nonlinear diffusion (319). 
 
Bubblegram and tomo-bubblegram Imaging 
Dose-series of HIV-1 particles were acquired either on a CM200-FEG TEM (FEI), 
operating at 120 keV with doses of ~17 e-/Å2 per exposure; or in a Tecnai-12 TEM operating at 
120 keV at ~5e-/Å2 per exposure. All images were collected on 2,048- by 2,048-pixel CCD 
cameras. Filled cores and eccentric aggregates bubbled at average doses of 165 ± 40 e-/Å2, 
n=109. The procedure used to collect and analyze data for tomo-bubblegram imaging is 
described in the Results section. The distances from the bubble centers to the center of the viral 
Env were measured using Bsoft programs. Briefly, after extracting and centering a virion, its 
radius was estimated: First, to eliminate the missing wedge, particles were symmetrized 
(icosahedral symmetry, which is not present in HIV-1 virions, was used for ease of analysis; this 
symmetry renders an almost spherical particle, like the ones selected for this analysis, into a 
featureless sphere). Then the radius was estimated from a density profile of the averaged particle. 
The bubble centers were then selected manually in the tomo-bubblegram, using the BshowX 
utility, and the distances of the bubbles from the Env were calculated by subtracting the distance 
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from the center of the bubble to the center of the particle from the particle radius at the middle of 
the Env. Isosurface rendering of viral particles was done in Chimera (320). NC was purified as 
previously described (321) and lyophilized after adding one equivalent Zn2+ per zinc finger. NC 
was then resuspended in buffer (25 mM HEPES, 30 mM NaCl, 1 mM MgCl2, 3 mM DTT and 
10% of glycerol at pH 7.5) at a concentration of 10 µM, aliquoted, and immediately frozen and 
stored at -80ºC until used. For cryo-EM, thawed aliquots (25 µl) were centrifuged at maximum 
speed for 5 min in a tabletop centrifuge and the top 20 µl were discarded. The remaining 5 µl 
was applied to a 400 mesh copper grid covered with a thin carbon film supported by a thick lacey 
carbon film, washed with buffer (25 mM HEPES, 10 mM NaCl, 1 mM MgCl2, pH 7.5) to 
remove the glycerol and plunge-frozen and imaged in a Tecnai-12 EM as described above. 
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Abstract 
 
HIV-1 selectively integrates into the bodies of active genes as opposed to within 
promoters. This preference is largely manifested through interaction of the HIV-1 intasome (IN 
tetramer and vDNA) with host cellular co-factor LEDGF/p75. ALLINIs, which inhibit HIV-1 
replication, target the interface of two IN molecules within the same binding pocket that 
LEDGF/p75 engages. Consistently, ALLINIs have been found to compete for LEDGF/p75 
binding in vitro and to display weak antiviral activity when integration occurs within the early 
stages of HIV-1 replication. Yet, the main antiviral activity of ALLINIs occurs at the late stage 
of the viral lifecycle through inhibition of maturation. Therefore, we were interested in 
determining whether compound-treated viruses would result in altered integration site 
distribution within the subsequent infection. We found that ALLINI treatment did indeed cause 
changes in integration site distributions, an effect that was not dependent upon time of exposure 
to the compounds (drug exposure limited to early versus late phase of the lifecycle), but rather to 
the percent of inhibition of infection and the particular ALLINI utilized. Since a potent ALLINI 
used at inhibiting concentration demonstrated a tendency to alter integration site distribution, 
further attention concerning this phenotype should be provided to ALLINI compounds within the 
pipeline for clinical development. 
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Introduction  
Despite HIV-1 unstintingly integrating vDNA into the genome of a susceptible host cell 
within an infected individual, an HIV-1 infection is not associated with directly causing cancer 
(322). The propensity for HIV-1 to target integration into the bodies of active genes is thought to 
be one reason as to why the DNA-integrating virus is specifically able to avoid insertional 
activation of proto-oncogenes (323). Four molecules of the viral protein IN will interact with 
vDNA to form an intasome-- the catalytically active entity responsible for mediating retroviral 
integration (129, 134, 144). Interaction of the intasome with host cellular cofactor LEDGF/p75, 
specifically within a defined pocket formed by the interface of two IN molecules, plays a critical 
role in directing HIV-1 integration into active transcription units (reviewed in (241, 242)). This 
defined pocket has recently been established as a feasible drug target (reviewed in (324)).  
ALLINIs are a promising group of small molecule compounds that inhibit HIV-1 
replication through modifying IN oligomerization (230-235, 284, 286). Surprisingly, although 
maintaining a weak activity during the early stages of HIV-1 replication in which integration 
occurs, the primary antiviral activity of ALLINIs occurs through stabilizing higher-ordered IN 
multimers during HIV-1 maturation (228, 233-235, 284, 286). Viruses made in the presence of 
the small molecules are unable to properly encapsidate their vRNP complex within a protective 
capsid core (325). These aberrant viruses are then defective for reverse transcription (228, 233, 
284, 286) and integration (225, 228, 230, 233, 234, 284, 286) within the subsequent infection. 
ALLINIs engage IN within the same defined pocket as LEDGF/p75, essentially mimicking the 
exact covalent bond interactions as those of the host factor (reviewed in (324)). As ALLINIs 
compete for LEDGF/p75 binding in vitro (230, 232) and display weak activity during the early 
phase of HIV-1 replication, it is plausible that they could influence integration site distribution. 
	   101	  
Since an alteration of integration site distribution could influence the propensity to avoid 
insertional activation, precaution should be taken when attempting to modify an interaction(s) 
that may influence the signature HIV-1 integration site pattern.  
Prior studies on the influence of ALLINIs on HIV-1 integration site distribution have 
reported conflicting results. One study found a significant alteration of HIV-1 integration 
patterns, as defined by a change in the percent integration into genes, when cells were treated 
during the early phase of replication (228), whereas a separate study did not (235). Infections 
initiated with compound-treated virions have additionally not shown an effect on integration site 
distribution within either of the two reports (228, 235). Because of the differences within the 
literature, we sequenced integration sites following ALLINI exposure during both the early 
phase of HIV-1 infection and during virus production. 
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Results 
ALLINIs can alter HIV-1 integration site patterns under certain infection conditions 
To further investigate the impact of ALLINI treatment on integration site distribution in 
an attempt to understand the discrepancies within the literature, we first completed infections 
where drug treatment was limited to the early stages of virus replication by exposing target cells 
to different doses of two representative ALLINIs: BI-D (236) and ALLINI-2, which is also 
known as BIB-2 (236) (Figure 1-6). We found that the percentage of integration sites in genes 
was modified by both inhibitors under this condition of drug exposure (Figure 4-1A and B). 
Interestingly, ALLINI-2 caused a decrease in the percentage of integrations into genes with an 
inhibitor dose as low as EC60 (Figure 4-1B), whereas BI-D did not show a difference in 
integration site distribution patterns at an EC60 drug dose, but did at the next tested drug dose 
where 85% of the infection was inhibited (Figure 4-1A). 
We next completed infections where drug exposure was limited to the late stages of virus 
replication by providing various drug doses of ALLINI-2 or BI-D during virus production and 
then exposing these viruses to susceptible host cells. Since the two previous integration site 
sequencing studies (228, 235) did not find an effect on integration site distribution under a single 
drug dose, we decided to complete a wide range of inhibitor doses in order to determine whether 
the percentage inhibited could contribute to the ability to see an effect as it did with BI-D when 
drug exposure was limited to the early phases of replication. Interestingly, we found that 
ALLINI-2 did not demonstrate a difference in integration site distribution under any drug dose 
tested (Figure 4-2B), whereas BI-D showed a decrease in the percentage of integrations into 
genes only with high inhibitor doses of EC95 or EC99 (Figure 4-2A). Although this finding was  
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Figure 4-1. Representative ALLINIs BI-D and ALLINI-2 retarget HIV-1 integration when 
exposure is limited to the early stages of the HIV-1 replication lifecycle 
Percent integrations into reference genes (n=1) determined from DNA extracted from SupT1 cell 
cultures 5-days postinfection with HIV-Luc that was made from HEK293T cells in the presence 
of DMSO, or EC60, EC80 or EC95 doses of BI-D (A) or ALLINI-2 (B). Realized percent 
infectivity at 48 h postinfection is reported on the x-axis (normalized to DMSO control). The 
percentage of integrations into reference genes of a computationally generated, matched random 
control sites would be 44.7%. P-values were determined utilizing Fisher’s extact test: * = p < 
0.01 and *** = p < 0.00001.  
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Figure 4-2. ALLINI BI-D retargets HIV-1 integration sites when exposure is limited to 
production under high percentage of inhibition 
Percent integrations into reference genes determined from DNA extracted from SupT1 cell 
cultures 5-days postinfection with HIV-Luc that was made from HEK293T cells in presence of 
DMSO or EC40, EC60, EC80, EC95 and EC99 doses of BI-D (A: representative data of 1 
experiment; n=6 for some data points) or ALLINI-2 (B). Realized percent infectivity at 48 h 
postinfection is reported on the x-axis (normalized to DMSO control).  The percentage of 
integrations into reference genes of a computationally generated, matched random control sites 
would be 44.7%. P-values were determined utilizing Fisher’s extact test: * = p < 0.01 and *** = 
p < 0.00001. 
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reproducible, 2 out of the 6 experiments failed to detect considerable differences in integration 
site distribution under these high inhibitor doses. 
 
The influence of LEDGF/p75 on integration retargeting by BI-D during HIV-1 production. 
Since we (233) and others (180, 228, 284, 326) have shown that LEDGF/p75 does not 
influence ALLINI potency during production, we were interested in determining whether 
LEDGF/p75 within the virus-producing cell played a role in the BI-D-induced alteration of HIV-
1 integration site distribution utilizing LEDGF/p75 knockout cells (LKOs) (180). We found that, 
independent of whether the target cells were LEDGF/p75 competent or depleted for the host 
factor, when LEDGF/p75 was not present in the producer cell (LKO virus; B1 versus B2 and B5 
versus B6) that we lost the ability for the drug to promote retargeting of integration into genes 
since there was not a difference between integration into reference genes when the virus was 
made in the presence of BI-D (B2 and B6) or was made in the presence of the DMSO control 
(B1 and B5) (Figure 4-3). By contrast when the virus was made from a cell that is LEDGF/p75 
competent (293T virus; B3 versus B4 and B7 versus B8), we regained the ability to influence 
retargeting within the subsequent target cell, as there was a considerable difference when virus 
was made in the presence (B4 and B8) or absence (B3 and B7) of BI-D. Consistently, this result 
was independent of whether the target cells were LEDGF/p75 competent or depleted for the host 
factor.  
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Figure 4-3. Retargeting of HIV-1 integration site distribution by BI-D exposure during 
virus production is dependent upon the expression of LEDGF/p75 within the virus-
producing cell 
Percent integrations in reference genes were determined in DNA extracted from cell cultures that 
were LEDGF/p75 depleted (LKO) or competent that had been infected with HIV-Luc virus that 
was produced in either LKO or 293T cells in the presence or absence of an EC50 dose of BI-D. 
Realized percent infectivity at 48 h postinfection is reported on the x-axis (normalized to DMSO 
control). The percentage of integrations into reference genes of a computationally generated, 
matched random control sites would be 44.7%. P-values were determined utilizing Fisher’s 
extact test: * = p < 0.05 and *** = p < 0.00001. 
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Discussion 
 
Because of conflicting results within the literature on the influences of ALLINIs on HIV-
1 integration site distribution (228, 235), we determined whether integration sites under infection 
conditions where ALLINI exposure was limited to either the early phase of HIV-1 infection or 
the late stages of the virus lifecycle— viral production. We found alterations of HIV-1 
integration site patterns to occur independent of time of drug exposure for one highly potent 
ALLINI, BI-D (Figure 4-1 and 4-2) (236). Although this finding was reproducible, only 4 out of 
the 6 experiments we completed determined considerable differences in integration site 
distribution. This inconsistency of results indicates that there may be an unconsidered infection 
property that is contributing to the ability to observe differences in integration site distribution 
and signifies that more work must be completed before definitive conclusions can be made. 
Similar to Sharma et al. (228), we found disruptions in integration site distribution to only occur 
when drug exposure was limited to the early stages of HIV-1 replication with another 
representative compound, ALLINI-2 (Figure 4-1 and 4-2) (237). Therefore, our results are 
supportive of Sharma et al. (228) who found an alteration of integration site patterns associated 
with HIV-1 when drug exposure was limited to the early stages of virus replication. In contrast to 
their work we also found an effect of inhibitor on the late stages of virus replication with 1 of 2 
representative ALLINI inhibitors in the majority of experiments completed.  
Because we completed multiple infections with a titration curve of BI-D exposure during 
virus production, we were able to determine the role that percentage of inhibition could be 
contributing to the discrepancies within the literature. In fact, the main differences between the 
different methods of infections was the percentage of inhibition achieved via the amount of 
inhibitor provided (~EC95 versus ~EC75 (228)). Interestingly, we found that integration site 
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patterns of BI-D treated viruses were only modified under infection conditions where the 
percentage of inhibition was 95-99% (Figure 4-2). The high level of inhibition needed to observe 
an effect indicates that compound treatment during production only influences a very small 
minority of virions, whose effects on integration sites can easily be masked by viruses that are 
not manipulated upon infections with less inhibitor/inhibition.  
We (233) and others (180, 228, 284, 326) have shown that LEDGF/p75 does not 
influence ALLINI potency during production. Therefore, in order to determine whether the 
critical host factor within virus-producing cells played a role in the BI-D-induced alteration of 
HIV-1 integration site distribution we observed when drug exposure was limited to production, 
we utilized LKOs as virus producer and/or susceptible target cells (180). Surprisingly, we found 
that the ability to retarget integration sites under infection conditions where a BI-D dose of EC95 
was provided during virus production was dependent upon the presence of LEDGF/p75 (Figure 
4-3). Therefore, our deep sequencing results indicate that LEDGF/p75 expression within the 
virus-producer cell appears to be especially important in the ability for BI-D to influence 
integration site distribution under infection conditions with a high percentage of inhibition during 
the late stage of HIV-1 replication.  
 Beyond a recent study that found LEDGF/p75 to be incorporated into HIV-1 viral 
particles (326), a role for LEDGF/p75 within the late stages of viral replication is not widely 
accepted within integration community. Established to be a substrate for HIV-1 protease, 
LEDGF/p75 is degraded after incorporation (326). Whether there is a proper role for 
LEDGF/p75 incorporation into the viral particle or rather incorporation is just a mere 
consequence of being an interacting partner with HIV-1 IN within the context of Gag-Pol is 
uncertain and requires further experimentation. Regardless, our results indicate that within a 
	   109	  
minority of virus particles, BI-D-induced retargeting of the HIV-1 integration pattern seen within 
a subsequent infection is apparently dependent upon the LEDGF/p75 that is incorporated into the 
viral particle. 
Since BI-D and not ALLINI-2 repeatedly, albeit within only 4 out of 6 experiments, 
yielded differences in integration patterns when exposure was limited to production suggests that 
a particular characteristic of the ALLINI inhibitor appears to be principally important in yielding 
effects on integration patterns. Because a relatively potent ALLINI may result in altered 
integration sites independent of the time of compound exposure, our results suggest that a more 
thorough investigation of this property should be mandatory prior to clinical application of these 
small molecule inhibitors. 
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Materials and Methods 
Plasmids, antivirals, and cells 
Single-round HIV-Luc was co-expressed from pNLX.Luc.R- (250) and the VSV-G 
glycoprotein was expressed using pCG-VSV-G (250). BI-D and ALLINI-2 were synthesized as 
described (236, 237). LEDGF/p75 knockout HEK293T cells were constructed as described (180). 
Transformed HEK293T cells (ATTC: CRL-3216) and LEDGF/p75 knockout HEK293T cells 
were grown in DMEM while human SupT1 T cells (NIH ARRRP item number 100) were 
maintained in RPMI medium 1640, both supplemented to contain 10% (vol/vol) FBS, 100 
IU/mL penicillin, and 100 µg/mL streptomycin.  
 
Viruses and antiviral assays 
HIV-Luc was produced by cotransfecting HEK293T cells (8 x 106) with 9 µg 
pNLX.Luc.R- and 1 µg pCG-VSV-G using PolyJet transfection reagent (SignaGen Laboratories). 
DMSO or ALLINIs were added with fresh media at ~17-20 h post transfection, and cell 
supernatants were collected 24 h later. Cell-free viruses were concentrated by ultracentrifugation 
(30,000 rpm at 4°C for 1.5 h using a Beckman SW41 rotor) and DNase-treated for 1 h at 37 °C. 
Virus concentrations were determined using a commercial p24 ELISA kit (Advanced 
Biosciences Laboratories). SupT1 cells (3 x 106) and HEK293T cells (3 x 105) were infected 
with 500 ng/mL p24 for 2 hours, after which infected cells were washed 1X in phosphate 
buffered saline solution and then replenished with fresh media. Luciferase values, expressed as 
relative light units, were determined 48 h postinfection and cells were harvested 5 days 
postinfection for DNA extraction. 
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Deep sequencing of HIV-1 integration sites 
DNA was extracted from SupT1 and HEK293T cells infected with ultrafiltered, DNase-
treated (1 h at 37 °C) HIV-Luc (100 ng p24/mL) using the DNeasy blood and tissue kit (Qiagen) 
5 days post-infection using the DNeasy Blood and Tissue Kit (Qiagen). Extracted DNA (20 µg) 
was then subjected to overnight digestion with MseI and BglII and subsequently purified using 
the QIAquick PCR Purification Kit (Qiagen). Double-stranded asymmetric linker DNA (1.5 µM) 
was made as described (327) and ligated with digested cellular DNA (1 µg) overnight at 16°C in 
four parallel reactions. The DNAs were then pooled and re-purified using the QIAquick PCR 
Purification Kit. Viral LTR-host genomic DNA junctions were amplified by seminested PCR.  
PCRs multiplexed into eight separate samples each contained 1 µg DNA substrate and first-
round HIV-1 LTR specific PCR primer and the linker specific primer in Advantage 2 PCR 
Buffer. The linker-specific primer is complementary to the annealed linker and contains the 
Illumina P7 adapter sequence. Completed PCR reactions were then pooled, PCR purified and 
subjected to the seminested PCR where the same linker-specific primer was utilized along with a 
second-round HIV-1 LTR specific PCR primer that additionally contained the Illumina P5 
adapter sequence. PCRs were then incubated at 94°C for 4 min, followed by six cycles at 94°C 
for 15 sec, 60°C for 30 sec, and 68°C for 45 sec. Reactions were then PCR cycled 24 times at 
94°C for 15 sec, 55°C for 30 sec, and 68°C for 45 sec, that was finally followed by an extension 
for 10 min at 68°C. Pooled PCRs were then purified using the QIAquick PCR Purification Kit 
and sequenced on the Illumina MiSeq platform at the Dana-Farber Cancer Institute Molecular 
Biology Core Facilities. 
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Bioinformatics analysis of integration sites 
Illumina reads were parsed for LTR-containing sequences. LTR sequences were then 
trimmed from each read with duplicates being removed from the trimmed reads and the resulting 
sequences were aligned to human reference genome hg19 by BLAT (328). Alignments with e 
values less than 0.05 and that matched starting from the first nucleotide after the LTR were 
selected. Bit scores (differences <0.0001) were used to remove multiple genomic sequences in 
order to identify unique alignments. The start position of the alignment on the positive strand 
was chosen as the insertion site, while 4 nucleotides were subtracted from the start position of 
alignments on the negative strand. Bedtools were used to calculate the gene densities for each 
insertion (329). An MRC dataset of 282,824 sites was created by selecting random genomic 
positions in proximity (<500 bp) of a AvrII, NheI or SpeI recognition site.   
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Mechanism of action for 2-(quinolin-3-yl) acetic acid derivatives 
X-ray co-crystallography (225, 228, 230, 232-235) and selection of resistance mutations 
(225, 226, 228, 230) within IN have revealed the binding site of ALLINIs to be at the interface 
of two IN monomers. ALLINIs specifically bind within a cavity formed by two IN CCDs in 
which the host factor LEDGF/p75 normally engages. Small molecule contact is accomplished 
through mirroring the critical interactions formed by LEDGF/p75 (hydrogen bonds formed from 
LEDGF/p75 residue Asp 366; Figure 1-5 and Figure 2-5). Although there is strong evidence that 
the molecular target of the compounds is IN, selection of ALLINI-resistance outside of IN could 
indirectly occur since multiple steps of the viral lifecycle are blocked (Chapter 2) and/or multiple 
viral proteins could be involved in the step inhibited (Figure 3-9). PR inhibitors have provided 
precedent for trans-protein drug resistance. PR inhibitors also cause replication blocks at 
multiple steps of the viral lifecycle, but the inhibitory potential appears to be especially 
important at entry (304). Consistently, in addition to finding PR inhibitor drug resistance 
mutations within PR, resistance mutations could also be found within the cytoplasmic tail of Env 
(304). Determining whether ALLINI resistance mutations can arise outside of the IN reading 
frame could be important in further elucidating the functional role of IN during maturation.  
By limiting compound exposure to a particular phase of HIV-1 replication through use of 
a single-round virus infection system, we were able to separate the effects of the investigational 
inhibitor on the early versus late stages of the virus lifecycle. Upon this analysis we found that 
the main antiviral activity of ALLINIs occurred during a late stage event; as drug potency of a 
spreading replication was retained only when the virus was produced in the presence of the 
inhibitor (during the late phase) (Figure 2-1 and Table 2-1) (233). This differs from INSTIs 
where drug potency of a spreading replication is retained when drug exposure is limited to the 
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acute phase of infection (during the early phase of replication) (Table 2-1) (233). Several other 
groups have since corroborated this conclusion with various ALLINI derivatives utilizing similar 
methodology (228, 235, 284) or through time of addition experiments (234, 286). This was 
somewhat of an unanticipated finding since the catalytic activity of IN occurs within the early 
phase of virus replication.   
 
Class II IN mutations: A foreshadowing for a role for IN within maturation 
IN amino acid substitutions in or around the LEDGF/p75 binding pocket, which resulted 
in disruption of the IN-LEDGF/p75 interaction, also demonstrated decreased viral fitness (114, 
184). Prior to detection of the dominant role for LEDGF/p75 during HIV-1 integration, the block 
in replication of these IN mutant viruses was originally proposed as evidence for the importance 
of the host factor during an infection (114). Yet, upon further breakdown, the block in replication 
was instead mapped to preintegrative steps (184). Rather than catalytic activity being defective, 
blocks in the ability to properly undergo reverse transcription were instead discovered (184). 
These findings indicated that introduction of missense mutations in or around the LEDGF/p75 
binding pocket resulted in the class II IN mutant virus phenotype, leading to the prediction a 
number of years ago that small molecule inhibitors that target this region may induce the class II 
IN phenotype— and cause pleiotropic perturbations within the HIV-1 lifecycle (183, 184). Thus, 
the late stage block of HIV-1 replication elicited by a small molecule that targets IN within the 
LEDGF/p75-binding pocket of ALLINIs was resonant of the preintegrative blocks induced by 
class II IN mutations.  
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ALLINIs exposure during production induces the class II IN mutant virus phenotype 
 In addition to blocking the integration step, ALLINI-treated viruses exhibited several 
defects along the HIV-1 replication pathway. As predicted, these replication blocks virtually 
mirrored those of class II IN mutant viruses: maturation/assembly (228, 233, 284, 286), reverse 
transcription (228, 233, 284, 286), and integration (225, 228, 230, 233, 234, 284, 286). Although 
multiple steps were inhibited, we found inhibitory potential was manifested at the maturation 
step (Figure 3-1). This finding indicates that when drug exposure is limited to production, the 
defects seen within reverse transcription and integration are a mere consequence of the 
aberrant/eccentric viral particle formed. The fact that ALLINIs only induce reverse transcription 
defects when exposure is limited to production (Figure 2-4), suggests that the influence on 
vDNA synthesis seems to occur prior to or immediately upon virus entry into target cells. 
ALLINIs do not inhibit RNA incorporation (233, 330), RT enzymatic activity (284, 330), its 
association with vRNA within the virion (284) or the placement of the tRNA primer on the 
vRNA genome (330). Therefore, we hypothesize that upon entry into the subsequent target cell, 
the lack of protective encasing provided by the capsid core leaves the vRNA, RT enzymes and/or 
the vDNA intermediates more vulnerable to diffusion into the milieu of the host cell cytoplasm. 
The absence of the protective capsid encapsidation around the vRNA within eccentric virions 
therefore directly affects reverse transcription efficacy within the subsequent infection-- resulting 
in the observed defects in early and late reverse transcript products (Figure 2-4). In addition to 
the lack of vDNA production limiting substrate availability for integration, without the protective 
capsid encasement IN would also face the diffusion challenge prior to association with the 
completed vDNA genome. This would account for our finding that the block of maturation of 
viruses made in the presence of ALLINIs serves as a bottleneck to the subsequent steps within 
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the HIV-1 replication lifecycle. With the wide range and large number of single point mutations 
that result in the class II IN phenotype (157), determining whether maturation underlies the HIV-
1 replication block of all class II IN mutants, could help to delineate whether all class II mutants 
are “alike” or if there can be further organization within the class. 
The one block of HIV-1 replication known to be associated with the class II IN mutant 
phenotype that was not found to be defective upon ALLINI exposure during production was 
virus release. Although virus release has been reported with some class II IN mutants, detection 
appears to be sensitive to cell-type used to produce the mutant viruses (157, 158, 250). The most 
common cell-type utilized to produce ALLINI treated viruses, HEK293T (180, 228, 233-235, 
284, 330), also does not elicit the virus release defect seen within some class II IN mutant viruses 
(157). However, defects in virus release upon ALLINI exposure were not observed using 
PBMCs (233), MT2 (284) or Jurkat cells (180), cell cultures that are more relevant than 
HEK293T cells when inferring results for HIV-1 replication within infected human hosts.  
 
LEDGF/p75 does not play a role in the potency of ALLINI 
ALLINI potency is realized because LEDGF/p75 does not compete for IN-binding during 
virus production. Since ALLINIs engage the IN dimer interface within the LEDGF/p75 binding 
pocket, the host factor can serve as a competitive threat to binding of the small molecule 
inhibitors. When the integration host factor is removed through knockdown (233, 284, 326) or 
knockout (180, 228), the strength of the compounds is modified during the early, but not the late 
stage of HIV-1 replication (where potency of a spreading replication is already realized) (Table 
2-1 & Table 2-2). This finding indicates that LEDGF/p75 only plays a competitive role with the 
inhibitors during the early stages of the viral lifecycle. LEDGF/p75 is a protein that is 
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constitutively bound to chromatin; therefore it is reasonable that it would primarily serve as a 
compromise to ALLINI potency only when in the same location-- after the PIC enters into the 
nucleus, but prior to strand transfer. Since potency is determined at the late stage of HIV-1 
replication, the mechanism of action of ALLINIs is LEDGF/p75 independent. 
There is a recent report that LEDGF/p75 can be incorporated into the HIV-1 particle 
through a direct interaction with the Gag-Pol polyprotein (326). Although the finding that 
ALLINI potency is LEDGF/p75-independent during the late stages of the virus lifecycle (180, 
228, 233, 284, 326) suggests that LEDGF/p75 incorporation during virus production must either 
be unstable (through quick degradation (326)) or not incorporated into particles at substantial 
levels. Interestingly, LEDGF/p75 overexpression within the virus-producing cell also did not 
result in a change of ALLINI potency (284). This finding further supports that there must be a 
particular block to the competitive role of LEDGF/p75 during virus production. This could 
potentially be explained through quick degradation upon PR activation within the maturing 
virion or a lack of substantial incorporation due to: 1. immediate localization of the surplus 
protein into the nucleus thereby limiting interaction opportunity or 2. lack of IN dimer interface 
of Gag-Pol within cellular milieu. Understanding whether overexpression of LEDGF/p75 results 
in increased incorporation into the HIV-1 particle could be insightful into understanding the 
discrepancy that despite the apparent incorporation of LEDGF/p75 during virus production, there 
is no effect on ALLINI potency.  
 
ALLINIs function through inducing higher-ordered IN multimerization  
Consistent with in vitro work demonstrating ALLINI enhancement of the multimeric 
state of recombinant IN (230-232, 234, 235), compound treatment of virus-producing cells 
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stabilized an oligomeric form of IN within nascent virions (233, 284, 286). Regions within the 
CCD and CTD of IN promote stabilization of the aberrant higher ordered IN multimers in 
ALLINI-induced multimerization (235, 331). This differs from the IN tetramerization driven by 
LEDGF/p75, where interactions occur at interfaces within the CCD and NTD of IN (332, 333). 
Although the exact multimeric state of IN within untreated HIV-1 particles is unknown, the 
estimated concentration of IN within virions is 20 mg/mL (324) suggesting that IN would likely 
exist within an oligomeric form. Our findings, along with others, indicate that stabilization of a 
higher-ordered form of IN upon ALLINI exposure during virus production results in disruption 
of proper RNP positioning within the capsid core, generating the observed eccentric morphology.  
Complete genetic removal of IN from the virus (HIV-Luc.ΔIN) also causes an increase in 
the incidence of the eccentric morphology (Figure 2-3) (233). In an attempt to demonstrate the 
direct role of IN in the mislocalization of the RNP seen within eccentric viruses, we extended 
TEM analysis of Vpr-IN transcomplemented HIV-Luc.ΔIN viruses. The partial rescue of the 
electron-dense core indicates that IN indeed has a direct role in normal core formation (Figure 3-
8). The protein-processing defects associated with HIV-Luc.ΔIN progeny (Figure 2-2) (233), 
likely precludes complete rescue of electron-dense cores. Consistently, ALLINI treatment of 
transcomplemented viruses then reversed the partial rescue of electron-dense cores, resulting in a 
phenocopy of untranscomplemented HIV-Luc.ΔIN. This result indicates that ALLINI exposure 
during production results in phenotypic removal or “barring” of IN within the virion (Figure 3-8). 
ALLINI stabilization of higher-ordered IN multimers could result in a physical 
obstruction within the virion that instigates disruptive maturation, which is ultimately shown in 
the mislocalization of the RNP seen within eccentric viruses. Or perhaps by phenotypic removal 
of IN through formation of ALLINI-induced higher-order multimers, IN is no longer able to 
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interact with an IN-binding partner(s) that is critical for proper RNP encapsidation to proceed. In 
support of the second model, we found the ability for the small molecules to induce the eccentric 
morphology during virus production to be dependent upon the HIV-1 vRNA substrate 
incorporated within the virion (Figure 3-7).  This suggests that IN must be interacting with the 
HIV-1 RNA genome in a specific manner and disruption of this interaction through stabilization 
of higher-order IN results in the lack of proper core encapsidation. Therefore, I predict IN plays 
an active role in vRNA incorporation into the mature CA core. 
 
In summary, through engaging the IN-IN interface within the LEDGF/p75 binding pocket, 
ALLINIs promote higher-order IN multimerization within the maturing virion in a LEDGF/p75-
independent manner. This uncouples IN from its presumed usual role during maturation, and 
ultimately results in a mislocalized RNP to outside of the mature CA core. This aberrant, 
eccentric virion form is then incapable of proper reverse transcription and integration within the 
subsequent infection.   
 
ALLINIs perturb proper integration site distribution  
Conflicting results have been published concerning the effect of ALLINIs on HIV-1 
integration site distribution. One report indicated a perturbation of integration site distribution 
only when drug exposure limited to the early stages of virus replication (228), whereas the other 
found no effect of ALLINIs despite time of compound exposure (235). We have continued to 
add to the dissimilarity of results, but in a manner that may resolve the inconsistencies within the 
literature. We find alterations of HIV-1 integration site patterns to occur independent of time of 
drug exposure within the majority of experiments (Figure 4-1 and 4-2). Therefore, our results are 
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supportive of the Sharma et al. (228) finding of disruptive integration site patterns when drug 
exposure is limited to the early stages of virus replication, but in contrast to their work we also 
found an effect of inhibitor on the late stages of virus replication for 1 of 2 representative 
ALLINIs (Figure 4-2). Although, in order to observe a late stage effect on integration patterns, 
we found the percentage of inhibition along with the particular ALLINI derivative utilized to be 
important. We specifically needed the percentage of inhibition through compound treatment 
during production to be 95-99% to observe a substantial effect on integration site distribution 
within the late stages of replication (Figure 4-2).  Both previously published reports (228, 235) 
did not achieve this level of inhibition, which could potentially explain the discrepancy between 
our finding and the past two studies in regards to ALLINI treatment during production. The high 
level of inhibition needed in order to observe an effect indicates that ALLINI treatment during 
production only influences a very small minority of virions, whose influences on integration sites 
can easily be masked by viruses that are not affected upon infections with less 
inhibitor/inhibition (Figure 4-2). Further, only one of the two inhibitors examined yielded 
differences of integration patterns within 4 of 6 experiments, indicating that a particular 
characteristic of the ALLINI appears to be principally important in yielding effects on 
integration patterns within the subsequent cell when treatment is administered during virus 
production. Further experimentation must be taken in order to determine mechanistic 
aspects/compound characteristics/infection conditions that contribute to uncovering a meaningful 
difference in integration site distribution upon ALLINI drug treatment during virus production 
prior to definitive conclusions being drawn. Regardless, because a relatively potent ALLINI 
resulted in altered integration sites independent of the time of compound exposure in the 
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majority of experiments completed, our results suggest attention should be paid to modifications 
of integration site distributions when considering compounds for clinical development. 
Through use of LEDGF/p75 knockout cells we were able to pinpoint LEDGF/p75 
expression within the producer cell to be especially important in ALLINI influence of integration 
site distribution during the late stage of HIV-1 replication (Figure 4-3). This was a particularly 
surprising finding since we and others have shown that ALLINI potency is not affected through 
LEDGF/p75 depletion (180, 228, 233, 284, 326) or overexpression (284). Although a role for 
LEDGF/p75 in HIV-1 replication beyond integration has yet to be found, LEDGF/p75 is 
incorporated into the HIV-1 particle through a direct interaction with the Gag-Pol polyprotein, 
but is degraded by HIV-1 PR within the virion (326). Interestingly, LEDGF/p75 was found to 
reverse ALLINI-induced aberrant higher-ordered IN multimerization, likely through competitive 
binding (332).  Thereby perhaps within a minority of cases, by competing for the LEDGF/p75 
binding site at the interface of the IN dimer, incorporation of LEDGF/p75 provides protection 
and/or destabilizes the ALLINI-induced IN multimer resulting in a subset of IN molecules still 
capable of interacting with vDNA. As LEDGF/p75 has been identified as a substrate for HIV-1 
PR (326), the host factor bound to the IN dimer interface may still be subject to PR degradation. 
This could potentially lead to an inactivated form of the IBD remaining within the LEDGF/p75 
binding pocket and ultimately result in preclusion of LEDGF/p75 binding to an IN dimer. The 
precluded IN dimer may still be capable of interaction with vDNA within the subsequent target 
cell and ultimately result in disruption of the normal HIV-1 integration pattern. Analysis of in 
vitro PR cleaved IN-LEDGF/p75 could be helpful in determining the validity of this working 
model for describing how ALLINI exposure during production influences integration site 
distribution within a LEDGF/p75-dependent manner in a minority of cases. 
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Outlook for current allosteric integrase inhibitors 
The primary weakness of the current repertoire of reported ALLINI derivatives is the 
tendency for viruses to quickly develop resistance mutations to the compounds in vitro. In 
reported ALLINI resistance studies to-date only five to six serial passages of HIV-1 virus in the 
presence of the small molecule compound were needed to select for inhibitor-resistant viruses 
(225, 228, 230). Since ALLINIs target an allosteric region as opposed to a catalytic site, a 
mutation within the host-factor binding pocket may be more tolerable as opposed to a mutation 
that directly influences catalytic activity.   
An HIV-1 infection does not directly cause cancer (323). The propensity for HIV-1 to 
target integration into the bodies of active genes is thought to be one reason as to why the DNA-
integrating virus is specifically able to avoid insertional activation of proto-oncogenes (323). 
Since alteration of integration site distribution could influence the propensity to avoid insertional 
activation and a relatively potent ALLINI resulted in altered site distribution independent of the 
time of compound exposure with infections of high ALLINI inhibition within the majority of 
experiment completed (Figure 4-1 and 4-2), concern should likely be paid when determining 
whether a compound would be an appropriate candidate for translation into the clinic. 
 MINIs are modified ALLINIs (pyridine- versus quinoline-based compounds) that 
selectively inhibit the maturation step of replication as opposed to blocking the LEDGF/p75-IN 
interaction (228). Since inhibitory concentrations of MINIs do not influence LEDGF/p75 binding 
in vitro, these compounds should not alter integration site distribution regardless of drug 
exposure during early or late stages of virus replication. Although Sharma et al. failed to use a 
clinically relevant inhibitory concentration, as expected, there was no effect of inhibitor on HIV-
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1 integration site distribution at the concentration utilized (~EC75). Since inhibitory 
concentrations would be needed for use within an infected patient, further MINI studies would 
need to be completed on infections with higher percentages of inhibition to ensure integration 
site distribution remains the signature HIV-1 pattern. Regardless, since MINIs selectively inhibit 
the maturation step as opposed to blocking LEDGF/p75 binding (228), pyridine-based ALLINI 
compounds are likely the most promising, reported ALLINI to-date for continued development 
toward clinical use. 
Boehringer Ingelheim (BI) advanced the first ALLINI, BI 224436, to phase Ia clinical 
trials (229, 334, 335). Single rising doses of BI 224436 were administered in a randomized, 
double-blind study to determine the safety and pharmokinetics of the small molecule within 
healthy male volunteers (336). The placebo-controlled study demonstrated adequate plasma 
concentrations with doses up to 200 mg and compound administration was concluded to be safe 
(336). BI 224436 was then enrolled within Phase Ib trial in order to determine safety and 
pharmokinetics with multiple rising doses, but was withdrawn prior to completion with the 
specified safety issue being identified as a “change in clinical laboratory test parameters” (337).  
As clinical trials progressed, key optimization of BI 224436 by BI was focused on improving the 
low in vivo clearance seen within rats (338). Utilizing scaffold hopping through modifying the 
quinoline group to a pyridine-based compound, BI decreased biliary recirculation in rats, thereby 
successfully improving in vivo clearance (338). MINIs are also pyridine-based compounds (228) 
therefore the BI-developed group of pyridine-based compounds likely possess the similar 
property of selectively inhibiting the late stage events of HIV-1 replication as opposed to 
inhibiting LEDGF/p75 binding. Interestingly, Fader et al. (338) found that the modified pyridine-
based compounds appear to bind tighter to tetrameric IN substrates as opposed to dimeric IN 
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entities. This finding could potentially provide insight into the multimeric form of greater 
prevalence at the particular stages of replication (early versus late).  
  
Model for the role of IN during HIV-1 particle maturation 
The pleiotropic perturbations of class II IN mutant viruses were the first indication that 
IN may have a role that extends beyond its catalytic activity. The preintegrative defects at 
multiple steps of the viral lifecycle of class II IN mutant viruses have been understood for years 
(146), but the underlying aspects of IN within the late phase of replication has remained 
undefined. The large amount of mutations within all domains of IN that yield the class II 
phenotype (157) limited the deductive exploration for the role(s) of IN during production. Our 
findings (233), quickly followed by others (228, 234, 235, 284, 286), have reinvigorated the 
proposal and pursuit that IN may perform a role during maturation.  
We were the first in the literature to propose a direct role for IN during core 
morphogenesis (Figure 3-9). Based on data described within this dissertation, we predict that IN 
serves to nucleate vRNA incorporation into the mature core, specifically through nucleating CA 
formation around genomic vRNA. A role for the viral enzyme within core morphogenesis has 
yet to be properly established, yet high affinity binding of IN to RNA has previously been 
observed in vitro (161). In support for an IN-vRNA interaction(s) in core morphogenesis as 
hypothesized within our model, our data revealed a role for vRNA in ALLINI-induced eccentric 
condensate formation (Figure 3-7). Additionally, a potential biological role for an IN-CA 
interaction has been suggested through the discovery of a linkage between IN and CA sequences 
changes among HIV-1 strains within AIDS patients (313).  
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Cryo-ET work completed by de Maro et al. (290) utilized single-point mutations that 
prevent complete PR processing and revealed a link between the condensed NC-RNA and the 
immature CA lattice. This finding suggests that the NC-RNA remains attached to the CA lattice 
after PR processing-- implying the presence of a potential interaction or link between the 
partially cleaved lattice and the condensed NC-RNA. It is an attractive hypothesis to propose that 
IN is involved in the formation and/or stabilization of the link. Determining whether the link 
between the condensed NC-RNA and the immature CA lattice can still be formed under 
conditions that pharmacologically (ALLINI treatment during virus production) or genetically 
(use of a ΔIN mutant virus manipulation of IN by) manipulate IN within a manner that disrupts 
the late stage role of IN would be extremely informative in addressing whether the described 
link is indeed representative of the CA-IN-vRNA complex within our model. 
There are many unknowns that remain associated with our model: Are other viral particle 
components involved in the putative CA-IN-vRNA complex? Does the IN involved within the 
initiation model use IN within the context of Gag-Pol or is it post-cleavage IN? Does CA 
assembly begin at the wide or narrow end of the CA core? We hypothesize that IN alone as 
opposed to IN as a part of Gag-Pol is the responsible entity nucleating CA formation around 
genomic vRNA, since the compounds appear to functionally target post-cleavage IN (Figure 2-6). 
We also prefer the model where assembly begins at the wide end since the electron density is 
predominately found within this region of the virus particle (58) as well as initiation at the wide 
end would narrow down to give a CA cone of about the right length, as demonstrated by CA in 
the absence of a membrane in vitro (311). Further experimentation is needed to provide 
clarification to our model that poses an active role for IN in vRNA encapsidation during HIV-1 
maturation.  
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Concluding remarks 
Data described within this thesis have provided a somewhat unexpected answer that has 
rooted an even larger question. Through describing an unanticipated mechanism of action of a 
new class of small molecule inhibitor, we have reinstated the significance of a phenotype 
previously described primarily through genetics through now demonstrating that a 
pharmacological avenue can also lead to a similar phenotype. Our work has reinvigorated efforts 
on further uncovering the role of IN within the late stage of viral replication. With ALLINIs to 
continue to serve as biological probes and complement genetic work, we anticipate the role of IN 
during the late stage of virus replication to soon be fully elucidated.  
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